Section H - effective 1 October 2009 (text extract)

This is the text extract for Section H - effective 1 October 2009, browse documents here.

Pharmaceutical Management Agency

Update

New Zealand Pharmaceutical Schedule

Effective 1 October 2009 Section H cumulative for August, September and October 2009

Contents

Summary of PHARMAC decision effective 1 October 2009 ............................ 3 Clarithromycin for helcobacter pylori eradication.......................................... 6 Diabetes Management Products – subsidy changes, new listing ................... 6 Aprepitant – new listing ................................................................................ 7 Raltegravir potassium – new listing ............................................................... 7 Fosamax Plus – new strength subsidised ....................................................... 7 Tender awarded for latanoprost eye drops .................................................... 8 Spacer devices and masks ............................................................................. 8 Vitadol C fully subsidised .............................................................................. 8 Phytomenadione injection –subsidised for oral use ....................................... 8 Tender News .................................................................................................. 9 Looking Forward ........................................................................................... 9 Sole Subsidised Supply products cumulative to October 2009 .................... 10 New Listings ................................................................................................ 17 Changes to Restrictions ............................................................................... 19 Changes to Subsidy and Manufacturer’s Price............................................. 26 Changes to Brand Name ............................................................................. 30 Changes to Sole Subsidised Supply ............................................................. 30 Delisted Items ............................................................................................. 31 Items to be Delisted .................................................................................... 33 Section H changes to Part II ........................................................................ 35 Section H changes to Part IV ....................................................................... 44 Index ........................................................................................................... 45

Summary of PharmaC decisions

effeCtive 1 OCtOBer 2009 New listings (pages 17 to 18) • Clarithromycin (Klamycin) tab 500 mg - subsidy by endorsement – maximum of 14 tabs per prescription, subsidised for helicobacter pylori eradication • Blood glucose diagnostic test meter (CareSens POP and CareSens II) meter – subsidy by endorsement • Blood glucose diagnostic test strip (CareSens) blood glucose test strips x 50 and lancets x 5 – subsidy by endorsement • Heparin sodium (Pfizer) inj 1,000 iu per ml, 5 ml (10 and 50 inj pack) and inj 5,000 iu per ml, 5 ml • Heparanised saline (Pfizer) inj 10 iu per ml, 5 ml • Raltegravir potassium (Isentress) tab 400 mg – Special Authority – Hospital pharmacy [HP1] • Alendronate sodium with cholecalciferol (Fosamax Plus) tab 70 mg with cholecalciferol 5600 iu – Special Authority – Retail pharmacy • Aprepitant (Emend Tri-Pack) cap 2 x 80 mg and 1 x 125 mg – Special Authority – Retail pharmacy • Risperidone (Risperon) oral liq 1 mg per ml, 30 ml • Latanoprost (Hysite) eye drops 50 μg per ml, 2.5ml OP – Retail pharmacy – Specialist • Aminoacid formula without phenylalanine (PKU Anamix Infant) infant formula, 400 g OP – Special Authority – Hospital pharmacy [HP3] • Aminoacid formula without phenylalanine (PKU Lophlex LQ) liquid (berry, citrus and orange) 62.5 ml OP and 125 ml OP – Special Authority – Hospital pharmacy [HP3] • Elemental formula (Pepti Junior Gold) powder 450 g OP - Special Authority Hospital pharmacy [HP3] Changes to restrictions (pages 19 to 25) • Phytomenadione (Konakion MM) inj 2 mg per 0.2 ml and inj 10 mg per ml, 1 ml – also subsidised for oral administration • Clarithromycin tab 250 mg and grans for oral liq 125 mg per 5 ml – amended Special Authority criteria • Alendronate for osteoporosis – amended Special Authority criteria • Levodopa with carbidopa (Sinemet CR) tab long-acting 200 mg with carbidopa 50 mg – removal of Retail pharmacy-Specialist restriction • Mask for spacer device – amended restriction criteria • Spacer device – amended restriction criteria

Summary of PharmaC decisions – effective 1 October 2009 (continued) Decreased subsidy (pages 26 to 29) • Pioglitazone (Actos) tab 15 mg, 30 mg and 45 mg • Blood glucose diagnostic test strip (Accu-Chek Performa) blood glucose test strips • Calamine (ABM) crm, aqueous, BP; and lotn, BP • Leuprorelin (Eligard) inj 7.5 mg, 22.5 mg, 30 mg and 45 mg • Levodopa with carbidopa tab long-acting 200 mg with carbidopa 50 mg (Sinemet CR) and tab 250 mg with carbidopa 25 mg (Sinemet) • Carboplatin (Carboplatin Ebewe) inj 10 mg per ml, 45 ml and 10 mg per ml, 100 ml • Dorzolamide hydrochloride with timolol maleate (Cosopt) eye drops 2% with timolol maleate 0.5% increased subsidy (pages 26 to 29) • Hydrocortisone acetate (Colifoam) rectal foam 10 %, CFC free (14 applications) • Atropine sulphate (AstraZeneca) inj 600 μg, 1 ml • Vitamin A with Vitamins D and C (Vitadol C) soln 1000 u with Vitamin D 400 u and ascorbic acid 30 mg per 10 drops • Heparin sodium (Mayne) inj 5,000 iu per ml, 1 ml • Potassium chloride (Span-K) tab long-acting 600 mg • Clonidine TDDS 2.5 mg, 100 μg per day (Catapres-TTS-1); TDDS 5 mg, 200 μg per day (Catapres-TTS-2); and TDDS 7.5 mg, 300 μg per day (Catapres-TTS-3) • Clonidine hydrochloride (Catapres) tab 150 μg • Clonidine hydrochloride (Catapres) inj 150 μg per ml, 1 ml • Clobetasol propionate (Dermol) crm 0.05% and oint 0.05% • Betamethasone valerate (Beta Scalp) scalp app 0.1% • Clobetasol propionate (Dermol) scalp app 0.05% • Oxytocin (Syntocinon) inj 5 iu per ml, 1 ml and 10 iu per ml, 1 ml • Oxytocin (Syntometrine) inj 5 iu with ergometrine maleate 500 μg per ml, 1 ml • Hydrocortisone (Douglas) tab 5 mg and 20 mg • Methylprednisolone sodium succinate (Solu-Medrol) inj 500 mg • Flucloxacillin sodium (AFT) grans for oral liq 125 mg per 5 ml and 250 mg per 5 ml • Gentamicin sulphate (Pfizer) inj 40 mg per ml, 2 ml • Naproxen tab 250 mg (Noflam 250) and 500 mg (Noflam 500) • Baclofen (Pacifen) tab 10 mg • Quinine sulphate (Q 300) tab 300 mg

Summary of PharmaC decisions – effective 1 October 2009 (continued) • Morphine hydrochloride (RA-Morph) oral liq 1 mg per ml, 2 mg per ml, 5 mg per ml, and 10 mg per ml • Morphine sulphate (Sevredol) tab immediate-release 10 mg and 20 mg • Moclobemide (Apo-Moclobemide) tab 150 mg and 300 mg • Clonidine hydrochloride (Dixarit) tab 25 μg • Carboplatin (Carboplatin Ebewe) inj 10 mg per ml, 5 ml and 10 mg per ml, 15 ml • Carboplatin (Baxter) inj 1 mg for ECP • Sodium cromoglycate (Rex) nasal spray, 4%

6 Pharmaceutical Schedule - Update News

Clarithromycin for helcobacter pylori eradication

The Special Authority requirement for helicobacter pylori eradication therapy on clarithromycin 250 mg tablets will be removed from 1 October 2009. This is because clarithromycin 500 mg tablets will be listed with endorsement criteria for h. pylori from 1 October 2009. Please note that prescriptions are considered endorsed if clarithromycin is prescribed in conjunction with a proton pump inhibitor and either amoxicillin or metronidazole. This means clarithromycin (Klamycin) 500 mg tablets will be subsidised by endorsement with a maximum quantity of 14 tablets per prescription for eradication

of h. pylori. The existing clarithromycin Special Authority criteria for mycobacterial infections will remain unchanged. Losec Hp7 OAC will remain fully funded for the treatment of h. pylori although the supplier (AstraZeneca) has advised that it will discontinue this pack once its current stocks are exhausted (anticipated to be in May 2010).

Diabetes Management Products – subsidy changes, new listing

From 1 October 2009, the subsidy and price will be reduced for the Accu-Chek Performa brand of blood glucose diagnostic test strips. The Accu-Chek Performa brand of blood glucose diagnostics test meters will also remain fully subsidised. A confidential rebate will apply to the test strips and meters subsidised in the community. The CareSens II and CareSens POP blood glucose diagnostic test meters will be listed fully subsidised from 1 October 2009. These are compatible with the newly listed CareSens test strips. Lancets in combination with the supply of the CareSens brand of blood glucose diagnostic test strips will be fully subsidised from 1 October 2009. We understand that the supplier of CareSens intends to provide patients with the choice of a free meter swap out.

Pharmaceutical Schedule - Update News

Aprepitant – new listing

From 1 October 2009, the antiemetic aprepitant (Emend Tri-Pack) capsules will be fully subsidised under Special Authority criteria for patients undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy. See page 17 for further information.

Raltegravir potassium – new listing

The antiretroviral medication raltegravir potassium (Isentress) 400 mg tablets will be subsidised from 1 October 2009. Isentress will be subsidised under the same Special Authority criteria that apply to currently funded antiretrovirals (Non-nucleoside Reverse Transcriptase Inhibitors, Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors).

Fosamax Plus – new strength subsidised

A new strength of Fosamax Plus tablets (alendronate sodium 70 mg with cholecalciferol 5,600 iu) will be subsidised from 1 October 2009. It is subject to the same Special Authority criteria as for the existing strength of Fosamax Plus. The currently listed presentation of Fosamax Plus (alendronate sodium with cholecalciferol 2,800 iu) will be delisted in approximately 6 months.

8 Pharmaceutical Schedule - Update News

Tender awarded for latanoprost eye drops

From 1 October 2009 Hysite (latanoprost 50 µg per ml) 2.5 ml eye drops will be listed on the Pharmaceutical Schedule. Hysite is manufactured and supplied by Pfizer who also manufacture and supply the current brand Xalatan. Hysite will be the Sole Subsidised Supply brand of latanoprost 50 µg per ml eye drops from 1 March 2010 until 30 June 2012.

Spacer devices and masks

From 1 October 2009, the Pharmaceutical Schedule rule allowing spacer devices and masks to be subsidised on Wholesale Supply Order (WSO) when written by a DHB paediatrician will be removed. This change correctly aligns DHB budgetary expenditure for their own use of spacers and masks. DHB hospitals will be able to order via their own internal systems.

Vitadol C fully subsidised

Vitadol C oral solution (vitamin A with vitamins D and C) will be fully subsidised without restriction from 1 October 2009. This is a result of a concurrent subsidy increase and price decrease.

Phytomenadione injection – subsidised for oral use

Roche Products is discontinuing supply of their chewable phytomenadione 10 mg tablet formulation. As a result, phytomenadione injections will be subsidised for oral administration from 1 October 2009. This change is necessary as section 2.2.17 of the General Rules in the Pharmaceutical Schedule state that substances in a form intended for intravenous delivery, prescribed for a purpose other than by injection, are not subsidised unless specified in Sections B to G of the Schedule. PHARMAC notes that the medicine datasheet includes instructions on the oral use of the injection formulation. The Konakion MM brand of phytomenadione injections are registered for oral use.

tender News

Sole Subsidised Supply changes – effective 1 November 2009

Chemical Name Atenolol Atenolol Hydrocortisone Nevirapine Nevirapine Presentation; Pack size Tab 50 mg; 500 tab Tab 100 mg; 500 tab Powder; 25 g Oral suspension 10 mg per ml; 240 ml Tab 200 mg; 60 tab Sole Subsidised Supply brand (and supplier) Pacific Atenolol (Mylan) Pacific Atenolol (Mylan) ABM (ABM) Viramune Suspension (Beohringer Ingelheim) Viramune (Beohringer Ingelheim)

Looking forward

This section is designed to alert both pharmacists and prescribers to possible future changes to the Pharmaceutical Schedule. It may also assist pharmacists, distributors and wholesalers to manage stock levels. Possible decisions for implementation 1 November 2009 • Azathioprine (Azamun) tab 50 mg – price and subsidy increase • Blood glucose diagnostic test meter (On Call Advanced) – new listing • Blood glucose diagnostic test strips with lancets (On Call Advanced) – new listing • Codeine phosphate (Douglas) powder 25 g – price and subsidy increase • Lansoprazole (Solox) – price and subsidy decrease • Lithium carbonate (Douglas) cap 250 mg – price and subsidy increase • Mesalazine (Pentasa) tab long-acting 500 mg – price and subsidy decrease • Nitrazepam (Nitrados) tab 5 mg – price and subsidy increase • Oxazepam (Ox-Pam) tab 10 and 15 mg – price and subsidy increase

Sole Subsidised Supply Products – cumulative to October 2009

Generic Name

Acarbose Acetazolamide Allopurinol Alprazolam Amantadine hydrochloride Amlodipine Amoxycillin

Presentation

Tab 50 mg & 100 mg Tab 250 mg Tab 100 mg & 300 mg Tab 250 µg, 500 µg & 1 mg Cap 100 mg Tab 5 mg & 10 mg Drops 125 mg per 1.25 ml Inj 250 mg, 500 mg & 1 g Cap 250 mg & 500 mg

Brand Name Expiry Date*

Glucobay Diamox Apo-Allopurinol Arrow-Alprazolam Symmetrel Apo-Amlodipine Ospamox Paediatric Drops Ibiamox Apo-Amoxi Synermox AFT Ethics Aspirin Ethics Aspirin EC Atropt Arrow-Azithromycin Sandoz Fibalip Bicalox Lax-Tabs AFT Marcain Isobaric Marcain Heavy Miacalcic Calsource Calcium Folinate Ebewe Apo-Captopril Ranbaxy-Cefaclor Ranbaxy-Cefaclor Hospira Zinacef PSM Zetop Cetirizine-AFT Chlorsig Orion 2012 2011 2011 2010 2011 2011 2011 2010 2011 2011 2010 2011 2012 2011 2011 2011 2010 2011 2010 2011 2011 2011 2010 2010 2011 2011 2010 2011 2012 2011

Amoxycillin clavulanate Aqueous cream Aspirin Atropine sulphate Azithromycin Benzylpenicillin sodium (Penicillin G) Bezafibrate Bicalutamide Bisacodyl Brimonidine tartrate Bupivicaine hydrochloride Calcitonin Calcium Calcium folinate Captopril Cefaclor monohydrate Cefazolin sodium Cefuroxime sodium Cetomacrogol Cetirizine hydrochloride Chloramphenicol Chlorhexidine gluconate

Tab amoxycillin 500 mg with potassium clavulanate 125 mg Crm 500 g Tab dispersible 300 mg Tab 100 mg Eye drops 1% Tab 500 mg Inj 1 mega u Tab 200 mg Tab 50 mg Tab 5 mg Eye drops 0.2% Inj 0.5%, 4 ml Inj 0.5%, 8% glucose, 4 ml Inj 100 iu per ml, 1 ml Tab eff 1 g Inj 50 mg Tab 12.5 mg, 25 mg & 50 mg Cap 250 mg Grans for oral liq 125 mg per 5 ml Inj 500 mg & 1 g Inj 750 mg & 1.5 g Crm BP Tab 10 mg Oral liq 1 mg per ml Eye oint 1% Soln 4%

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to October 2009

Generic Name

Ciclopiroxolamine Ciprofloxacin Citalopram Clarithromycin Clonazepam Clotrimazole

Presentation

Nail soln 8% Tab 250 mg, 500 mg & 750 mg Tab 20 mg Tab 250 mg Grans for oral liq 125 mg per 5 ml Tab 500 µg & 2 mg Vaginal crm 2% with applicators(s) Crm 1% Vaginal crm 1% with applicator(s) Tab 15 mg, 30 mg & 60 mg Tab 500 µg Sach 5 g Inj 150 mg Powder for soln for oral use Tab 50 mg Tab 50 mg Tab 50 mg & 100 mg Inj 500 mg Nasal spray 10 mcg per dose Tab 5 mg Inj 50%, 10 ml Oral soln with electrolytes

Brand Name Expiry Date*

Batrafen Rex Medical Arrow-Citalopram Klamycin Klacid Paxam Clomazol Clomazol Clomazol PSM Colgout Colestid Colistin-Link Enerlyte Nausicalm Cycloblastin Siterone Mayne Desmopressin-PH&T PSM Biomed Pedialyte – Plain Pedialyte – Bubblegum Pedialyte – Fruit Voltaren Ophtha Voltaren Voltaren Dilzem Cardizem CD Pytazen SR Apo-Doxazosin AFT Clexane Comtan 2012 2011 2010 2010 2011 2010

Codeine phosphate Colchicine Colestipol hydrochloride Colistin sulphomethate Compound electrolytes Cyclizine hydrochloride Cyclophosphamide Cyproterone acetate Desferrioxamine mesylate Desmopressin Dexamphetamine sulphate Dextrose Dextrose with electrolytes

2010 2010 2010 2010 2010 2012 2010 2012 2010 2011 2010 2011 2010

Diclofenac sodium

Eye drops 1 mg per ml Inj 25 mg per ml, 3 ml Suppos 12.5 mg, 25 mg, 50 mg & 100 mg Tab 30 mg & 60 mg Cap long-acting 120 mg, 180 mg & 240 mg Tab long-acting 150 mg Tab 2 mg & 4 mg Oint BP Inj 20 mg, 40 mg, 60 mg, 80 mg, 100 mg, 120 mg & 150 mg Tab 200 mg

2011

Diltiazem hydrochloride

2011

Dipyridamole Doxazosin mesylate Emulsifying ointment Enoxaparin sodium (low molecular weight heparin) Entacapone

2011 2010 2011 2012 2012

Sole Subsidised Supply Products – cumulative to October 2009

Generic Name

Erythromycin ethyl succinate

Presentation

Tab 400 mg Grans for oral liq 200 mg per 5 ml Grans for oral liq 400 mg per 5 ml Tab 10 µg Tab 35 μg with norethisterone 500 µg Tab 35 μg with norethisterone 1 mg Tab 35 μg with norethisterone 1 mg and 7 inert tab Tab long-acting 5 mg Tab long-acting 10 mg Oral liq 150 mg per 5 ml Tab 5 mg Inj 250 mg, 500 mg & 1 g Cap 50 mg, 150 mg & 200 mg Inj 50 mg Tab 10 mg Oint 950 μg, with fluocortolone pivalate 920 μg, and cinchocaine hydrochloride 5 mg per g Suppos 630 μg, with fluocortolone pivalate 610 μg, and cinchocaine hydrochloride 1 mg Cap 20 mg Tab disp 20 mg, scored Tab 40 mg Crm 2% Oint 2% Cap 100 mg, 300 mg & 400 mg Tab 80 mg Tab 5 mg Tab 600 µg Oral pump spray 400 μg per dose TDDS 5 mg & 10 mg

Brand Name Expiry Date*

E-Mycin E-Mycin E-Mycin NZ Medical and Scientific Brevinor 21 Brevinor 1/21 Brevinor 1/28 Felo 5 ER Felo 10 ER Ferodan Fintral Flucloxin Pacific Fludara Fludara Oral Ultraproct Ultraproct 2012 2010 2011 2011 2011 2011 2010 2012 2011 2012 2010

Ethinyloestradiol Ethinyloestradiol with norethisterone

Felodipine Ferrous sulphate Finasteride Flucloxacillin Fluconazole Fludarabine phosphate Fluocortolone caproate with fluocortolone pivalate and cinchocaine

Fluoxetine hydrochloride Furosemide Fusidic acid Gabapentin Gliclazide Glipizide Glyceryl trinitrate

Fluox Fluox Diurin 40 Foban Foban Nupentin Apo-Gliclazide Minidiab Lycinate Nitrolingual pumpspray Nitroderm TTS Serenace Serenace PSM Locoid DP Lotn HC

2010 2012 2010 31/7/12 2011 2011 2011

Haloperidol Hydrocortisone Hydrcortisone butyrate Hydrocortisone with wool fat and mineral oil

Oral liq 2 mg per ml Tab 500 μg, 1.5 mg & 5 mg Crm 1% Scalp lotn 0.1% Lotn 1% with wool fat hydrous 3% and mineral oil

2010 2011 2010 2011

Sole Subsidised Supply Products – cumulative to October 2009

Generic Name

Hydroxychloroquine sulphate Hypromellose Hysocine N-butylbromide Ibuprofen Ipratropium bromide

Presentation

Tab 200 mg Eye drops 0.5% Inj 20 mg, 1 ml Tab 20 mg Tab 200 mg Oral liq 100 mg per 5 ml Aqueous nasal spray, 0.03% Nebuliser soln, 250 μg per ml, 1 ml Nebuliser soln, 250 μg per ml, 2 ml Inj 50 mg per ml, 2 ml Cap 100 mg Shampoo 2% Oral liq 10 g per 15 ml Eye drops 0.25% & 0.5% Inj 0.5%, 5 ml Inj 1%, 5 ml Inj 1%, 20 ml Crm 2.5% with prilocaine 2.5%; 30 g OP Crm 2.5% with prilocaine 2.5%; 5 g Tab 5 mg, 10 mg & 20 mg Tab 2 mg Tab 10 mg Oral liq 1 mg per ml

Brand Name Expiry Date*

Plaquenil Methopt Buscopan Gastrosoothe Ethics Ibuprofen Fenpaed Apo-Ipravent Ipratripium Steri-Neb Ipratripium Steri-Neb Ferrum H Sporanox Sebizole Duphalac Betagan Xylocaine Xylocaine Xylocaine EMLA EMLA Arrow-Lisinopril Nodia Loraclear Hayfever Relief Lorapaed Derbac M A-Lices Foremount Child’s Silicone Mask De-Worm Colofac Provera Pentasa Biodone Biodone Forte Biodone Extra Forte Methatabs Methoblastin Methotrexate Ebewe Methotrexate Ebewe 2012 2010 2010 2012 2011 2011 2012 2010 2010

Iron polymaltose Itraconazole Ketoconazole Lactulose Levobunolol Lignocaine hydrochloride

2011 2010 2011 2010 2010 2010

Lignocaine with prilocaine

2010

Lisinopril Loperamide hydrochloride Loratadine

Malathion Mask for Spacer Device Mebendazole Mebeverine hydrochloride Medroxyprogesterone acetate Mesalazine Methadone hydrochloride

Liq 0.5% Shampoo 1% Device Tab 100 mg Tab 135 mg Tab 2.5 mg, 5 mg, 10 mg, 100 mg & 200 mg Enema 1 g per 100 ml Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml Tab 5 mg Tab 2.5 mg & 10 mg Inj 100 mg per ml, 10 ml Inj 100 mg per ml, 50 ml

2010 2011 30/9/11 2011 2011 2010 2012 2012 2010 2012 2011

Methotrexate

Sole Subsidised Supply Products – cumulative to October 2009

Generic Name

Methyldopa Methylprednisolone Methylprednisolone acetate Methylprednisolone acetate with lignocaine Metoclopramide hydrochloride Miconazole nitrate Morphine sulphate Nadolol Naltrexone hydrochloride Naproxen sodium Neostigmine Nicotine

Presentation

Tab 125 mg, 250 mg, 500 mg Tab 4 mg & 100 mg Inj 40 mg per ml, 1 ml Inj 40 mg per ml with lignocaine 1 ml Inj 5 mg per ml, 2 ml Crm 2% Inj 10 mg per ml, 1 ml Inj 30 mg per ml, 1 ml Tab 40 mg & 80 mg Tab 50 mg Tab 275 mg Inj 2.5 mg per ml, 1 ml Patch 7 mg, 14 mg and 21 mg Lozenge 1 mg and 2 mg Gum 2 mg & 4 mg (Fruit) Gum 2 mg & 4 mg (Mint) Tab 350 µg Tab 5 mg Tab 10 mg & 25 mg Oral liq 100,000 u per ml, 24 ml OP Cap 500,000 u Tab 500,000 u Cap 10 mg, 20 mg & 40 mg Inj 40 mg

Brand Name Expiry Date*

Prodopa Medrol Depo-Medrol Depo-Medrol with Lidocaine Pfizer Multichem Mayne Mayne Apo-Nadolol ReVia Sonaflam AstraZeneca Habitrol Habitrol Habitrol Habitrol Noriday 28 Primolut N Norpress Nilstat Nilstat Nilstat Dr Reddy’s Omeprazole Dr Reddy’s Omeprazole Zofran Zofran Zydis Apo-Oxybutynin Apo-Oxybutynin OxyNorm OxyNorm Pamisol Pamisol Pamisol Pantocid IV Dr Reddy’s Pantoprazole Pharmacare Paracare Junior Paracare Double Strength 2011 2012 2011 2011 2011 2011 2011 2010 2010 2010 2010 2010

Norethisterone Nortriptyline hydrochloride Nystatin

2012 2011 2011 2011 2010 2011

Omeprazole

Ondansetron Oxybutynin Oxycodone hydrochloride Pamidronate disodium

Tab 4 mg & 8 mg Tab disp 4 mg & 8 mg Tab 5 mg Oral liq 5 mg per 5 ml Inj 10 mg per ml, 1 ml & 2 ml Oral liq 5 mg per 5 ml Inj 3 mg per ml, 5 ml Inj 3 mg per ml, 10 ml Inj 6 mg per ml, 10 ml Inj 40 mg Tab 20 mg & 40 mg Tab 500 mg Oral liq 120 mg per 5 ml Oral liq 250 mg per 5 ml

2010 2010 2010 2011

Pantoprazole

2010

Paracetamol

2011

Sole Subsidised Supply Products – cumulative to October 2009

Generic Name

Paraffin liquid with soft white paraffin Paroxetine hydrochloride Peak Flow Meter Pergolide Phenoxymethylpenicillin (Penicillin V) Phenylephrine hydrochloride Poloxamer Polyvinyl alcohol Prazosin hydrochloride Prednisone Procaine penicillin Promethazine Quinapril Quinapril with hydroclorothiazide

Presentation

Eye oint with soft white paraffin Tab 20 mg Low range and Normal range Tab 0.25 mg & 1 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Cap potassium salt 250 mg & 500 mg Eye drops 0.12% Oral drops 10% Eye drops 1.4% Eye drops 3% Tab 1 mg, 2 mg & 5 mg Tab 1 mg, 2.5 mg, 5 mg & 20 mg Inj 1.5 mega u Tab 10 mg & 25 mg Tab 5 mg, 10 mg & 20 mg Tab 10 mg with hydroclorothiazide 12.5 mg Tab 20 mg with hydroclorothiazide 12.5 mg Oral liq 150 mg per 10 ml Cap 150 mg Tab 0.25 mg, 1 mg, 2 mg and 5 mg Tab 150 mg & 300 mg Nebuliser soln, 1 mg per ml, 2.5 ml Nebuliser soln, 2 mg per ml, 2.5 ml Oral liq 2 mg per 5 ml Nebuliser soln, 2.5 mg with ipratopium bromide 0.5 mg per vial, 2.5 ml Tab 5 mg Tab 10 mg Tab 20 mg Tab 40 mg Tab 80 mg Grans eff 4 g sachets Tab 80 mg & 160 mg

Brand Name Expiry Date*

Lacri-Lube Loxamine Breath-Alert Permax AFT AFT Cilicaine VK Prefrin Coloxyl Vistil Vistil Forte Apo-Prazo Apo-Prednisone Redipred Cilicaine Allersoothe Accupril Accuretic 10 Accuretic 20 Peptisoothe Mycobutin Ropin ArrowRoxithromycin Asthalin Asthalin Salapin Duolin 2010 2010 2010 2012 2012 2010 2012 2010 2010 30/9/11 2011 2010

2010 2011 2011 2010 2011 2012 2011 2011 2011 2011

Prednisone sodium phosphate Oral liq 5 mg per ml

Ranitidine hydrochloride Rifabutin Ropinirole hydrochloride Roxithromycin Salbutamol

Salbutamol with ipratropium bromide Selegiline hydrochloride Simvastatin

Apo-Selegiline Arrow-Simva 10 mg Arrow-Simva 20 mg Arrow-Simva 40 mg Arrow-Simva 80 mg Ural Mylan

2012 2011

Sodium citro-tartrate Sotalol

2010 2012

Sole Subsidised Supply Products – cumulative to October 2009

Generic Name

Spacer Device Syrup (pharmaceutical grade) Tar with triethanolamine lauryl sulphate and fluorescein Temazepam Terazosin hydrochloride Terbinafine Testosterone cypionate Tetracosactrin Timolol maleate Triamcinolone acetonide

Presentation

230 ml Liq Soln 2.3% Tab 10 mg Tab 2 mg & 5 mg Tab 250 mg Inj long-acting 100 mg per ml, 10 ml Inj 250 mcg Inj 1 mg per ml, 1 ml Tab 10 mg Eye drops 0.25% & 0.5% Crm 0.02% Oint 0.02% Inj 40 mg per ml, 1 ml 0.1% in Dental Paste USP Tab 300 mg Cap 300 mg Inj 50 mg per ml, 10 ml Ointment BP Cap 220 mg Tab 7.5 mg

Brand Name Expiry Date*

Space Chamber Midwest Pinetarsol Normison Apo-Terazosin Apo-Terbinafine Depo-Testosterone Synacthen Synacthen Depot Apo-Timol Apo-Timop Aristocort Aristocort Kenacort-A40 Oracort TMP Actigall Pacific PSM Zincaps Apo-Zopiclone 30/9/11 2010 2011 2011 2010 2011 2011 2011 2012 2011 2011 2011 2011 2011 2011 2011 2011 2011

Trimethoprim Ursodeoxycholic acid Vancomycin hydrochloride Zinc and castor oil Zinc sulphate Zopiclone October changes in bold

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings

Effective 1 October 2009

27 CLARITHROMYCIN Tab 500 mg – Subsidy by endorsement .................................. 23.30 14 ✔ Klamycin a) Maximum of 14 tablets per prescription b) Subsidised only if prescribed for helicobacter pylori eradication and prescription is endorsed accordingly. Note: the prescription is considered endorsed if clarithromycin is prescribed in conjunction with a proton pump inhibitor and either amoxycillin or metronidazole. BLOOD GLUCOSE DIAGNOSTIC TEST METER – Subsidy by endorsement a) Maximum of 1 meter per prescription b) 1) A diagnostic blood glucose test meter is subsidised for patients who begin insulin or sulphonylurea therapy after 1 March 2005 or is prescribed for a pregnant woman with diabetes. 2) Only one meter per patient. No further prescriptions will be subsidised. The prescription must be endorsed accordingly. Meter ....................................................................................... 6.00 1 ✔ CareSens POP 9.00 ✔ CareSens II BLOOD GLUCOSE DIAGNOSTIC TEST STRIP The number of test strips available on a prescription is restricted to 50 unless: 1) Prescribed with insulin or a sulphonylurea but are on a different prescription and the prescription is endorsed accordingly; or 2) Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; or 3) Prescribed for a pregnant woman with diabetes and endorsed accordingly. Blood glucose test strips x 50 and lancets x 5 .......................... 19.60 1 OP ✔ CareSens HEPARIN SODIUM Inj 1,000 iu per ml, 5 ml ......................................................... 11.44 46.30 Inj 5,000 iu per ml, 5 ml ....................................................... 118.50 HEPARINISED SALINE ❋ Inj 10 iu per ml, 5 ml .............................................................. 32.50 10 50 50 50 ✔ Pfizer ✔ Pfizer ✔ Pfizer ✔ Pfizer

42 93 106 117

RALTEGRAVIR POTASSIUM – Special Authority see SA0779 – Hospital pharmacy [HP1] Tab 400 mg ....................................................................... 1,350.00 60 ✔ Isentress ALENDRONATE SODIUM WITH CHOLECALCIFEROL – Special Authority see SA0990 – Retail pharmacy Tab 70 mg with cholecalciferol 5600 iu ................................... 35.91 4 ✔ Fosamax Plus APREPITANT – Special Authority see SA0987 – Retail pharmacy Cap 2 x 80 mg and 1 x 125 mg ............................................. 116.00 3 OP ✔ Emend Tri-Pack ➽ SA0987 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy. Renewal from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy.

123

RISPERIDONE Oral liq 1 mg per ml ................................................................ 18.35

30 ml

✔ Risperon

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New listings - effective 1 October 2009 (continued)

159 LATANOPROST – Retail pharmacy-Specialist See prescribing guideline ▲ Eye drops 50 μg per ml, 2.5ml ................................................. 9.75

2.5 ml OP ✔ Hysite

186

AMINOACID FORMULA WITHOUT PHENYLALANINE – Special Authority see SA0733 – Hospital pharmacy [HP3] See prescribing guideline Infant formula ........................................................................ 174.72 400 g OP ✔ PKU Anamix Infant Liquid (berry) .......................................................................... 15.65 62.5 ml OP ✔ PKU Lophlex LQ 31.20 125 ml OP ✔ PKU Lophlex LQ Liquid (citrus) .......................................................................... 15.65 62.5 ml OP ✔ PKU Lophlex LQ 31.20 125 ml OP ✔ PKU Lophlex LQ Liquid (orange) ........................................................................ 15.65 62.5 ml OP ✔ PKU Lophlex LQ 31.20 125 ml OP ✔ PKU Lophlex LQ ELEMENTAL FORMULA – Special Authority see SA0603 – Hospital pharmacy [HP3] Powder ................................................................................... 11.72 450 g OP (15.21)

187

Pepti Junior Gold

Effective 1 September 2009

32 INSULIN PEN NEEDLES – Maximum of 100 dev per prescription ❋ 29 g × 12.7 mm .................................................................... 11.75 ❋ 31 g × 5 mm ......................................................................... 11.75 ❋ 31 g × 8 mm ......................................................................... 11.75 100 100 100 ✔ SC Profi-Fine ✔ SC Profi-Fine ✔ SC Profi-Fine

INSULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE – Maximum of 100 dev per prescription ❋ Syringe 0.3 ml with 29 g × 12.7 mm needle .......................... 13.00 100 ✔ DM Ject ❋ Syringe 0.3 ml with 31 g × 8 mm needle ............................... 13.00 100 ✔ DM Ject ❋ Syringe 0.5 ml with 29 g × 12.7 mm needle .......................... 13.00 100 ✔ DM Ject ❋ Syringe 0.5 ml with 31 g × 8 mm needle ............................... 13.00 100 ✔ DM Ject ❋ Syringe 1 ml with 29 g × 12.7 mm needle ............................. 13.00 100 ✔ DM Ject 100 ✔ DM Ject ❋ Syringe 1 ml with 31 g × 8 mm needle .................................. 13.00 CLOPIDOGREL – Special Authority see SA0867 – Retail pharmacy Tab 75 mg .............................................................................. 25.00 ISOTRETINOIN – Special Authority see SA0955 – Retail pharmacy Cap 10 mg .............................................................................. 48.48 Cap 20 mg ............................................................................. 69.70 TESTOSTERONE UNDECANOATE – Retail pharmacy-Specialist Cap 40 mg .............................................................................. 60.71 BROMOCRIPTINE MESYLATE ❋ Cap 5 mg ............................................................................... 60.43 ZUCLOPENTHIXOL HYDROCHLORIDE Tab 10 mg .............................................................................. 31.45 28 180 180 60 100 ✔ Arrow-Clopidogrel ✔ Oratane ✔ Oratane ✔ Andriol Testocaps ✔ Apo-Bromocriptine

S29

40 58

76 119

123

100

✔ Clopixol

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions

Effective 1 October 2009

40 PHYTOMENADIONE Inj 2 mg per 0.2 ml – Up to 5 inj available on a PSO ................... 8.00 May be administered orally Inj 10 mg per ml, 1 ml – Up to 5 inj available on a PSO .............. 9.21 May be administered orally 5 5 ✔ Konakion MM ✔ Konakion MM

CLARITHROMYCIN – Maximum of 500 mg per prescription; can be waived by Special Authority see SA0988 0657 Tab 250 mg ............................................................................. 7.75 14 ✔ Klamycin Grans for oral liquid 125 mg per 5 ml ...................................... 23.12 70 ml ✔ Klacid ➽ SA0988 0657 Special Authority for Waiver of Rule Initial application — (Helicobacter pylori infections) only from a general practitioner or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Eradication of Helicobacter pylori in patient with proven infection; and 2 Peptic ulcer disease proven by endoscopy. Note: Maximum of two prescriptions (two courses) per patient. Initial application — (Mycobacterial infections) only from a respiratory specialist, infectious disease specialist or paediatrician. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Mycobacterium Avium Intracellulare Complex infections in patient with AIDS; or 2 Atypical and drug-resistant mycobacterial infection; or 3 All of the following: 3.1 Prophylaxis against disseminated Mycobacterium Avium Intracellulare Complex infection; and 3.2 HIV infection; and 3.3 CD4 count ≤ 50 cells/mm3. Renewal —(Mycobacterial infections) only from a respiratory specialist, infectious disease specialist or paediatrician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

105

ALENDRONATE FOR OSTEOPOROSIS ➽ SA0990 0948 Special Authority for Subsidy Initial application — (Underlying cause – Osteoporosis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mass density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5); or 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or 3 History of two significant osteoporotic fractures demonstrated radiologically; or 4 Documented T-Score ≤ -3.0; or 5 A 10-year risk of hip fracture ≥ 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Dubbo) which incorporates BMD measurements. Initial application — (Underlying cause – glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: continued...

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 October 2009 (continued)

continued... 1 The patient is receiving systemic glucocorticosteriod therapy (≥ 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and 2 Either: 2.1 The patient has documented BMD ≥ 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -1.5); or 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically. Renewal —(Underlying cause was, and remains, glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year where the patient is continuing systemic glucocorticosteriod therapy (≥ 5 mg per day prednisone equivalents). Renewal — (Underlying cause was glucocorticosteroid therapy but patient now meets the ’Underlying cause osteoporosis’ criteria) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mass density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5); or 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or 3 History of two significant osteoporotic fractures demonstrated radiologically; or 4 Documented T-Score ≤ -3.0; or 5 A 10-year risk of hip fracture ≥ 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Dubbo) which incorporates BMD measurements. Notes: a) Evidence used by National Institute for Health and Clinical Excellence (NICE) guidance indicates that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5, and therefore do not require BMD measurement for treatment with bisphosphonates. b) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less. c) In line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body. 119 LEVODOPA WITH CARBIDOPA ❋ Tab long-acting 200 mg with carbidopa 50 mg – Retail pharmacy-Specialist ................................................................ 47.50

100

✔ Sinemet CR

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 October 2009 (continued)

156 MASK FOR SPACER DEVICE a) Maximum of 20 dev per WSO b) Only on a WSO c) 1) Spacer devices and masks also available to paediatricians employed by a DHB on a wholesale supply order signed by the paediatrician. Limited to one pack of 20 per order. Orders via a hospital pharmacy. 12) Only available for children aged six years and under. 23) For Space Chamber and Foremount Child’s Silicone Mask wholesale supply order must indicate clearly if either the spacer device, the mask, or both are required. 34) Distributed by Airflow Products. Forward orders to: Airflow Products Telephone: 04 499 1240 or 0800 AIR FLOW PO Box 1485, Wellington Facsimile: 04 499 1245 or 0800 323 270 Size 2 ........................................................................................ 3.28 1 ✔ Foremount Child’s Silicone Mask SPACER DEVICE a) Maximum of 20 dev per WSO b) Only on a WSO c) 1) Spacer devices and masks also available to paediatricians employed by a DHB on a wholesale supply order signed by the paediatrician. Limited to one pack of 20 per order. Orders via a hospital pharmacy. 12) For Space Chamber and Foremount Child’s Silicone Mask wholesale supply order must indicate clearly if either the spacer device, the mask, or both are required. Space Chamber distributed by Airflow Products. Forward orders to: Airflow Products - PO Box 1485, Wellington Telephone: 04 499 1240 or 0800 AIR FLOW, Facsimile: 04 499 1245 or 0800 323 270 Volumatic Distributed by GlaxoSmithKline. Forward orders to: Telephone: 0800 877 789 Facsimile: 0800 877 785 230 ml (autoclavable) – Subsidy by endorsement .................... 11.60 1 ✔ Space Chamber Available where the prescriber requires a spacer device that is capable of sterilisation in an autoclave and the WSO is endorsed accordingly. 230 ml (single patient) .............................................................. 8.38 1 ✔ Space Chamber 800 ml ..................................................................................... 8.50 1 ✔ Volumatic

156

Effective 1 September 2009

31 KETONE BLOOD BETA-KETONE ELECTRODES – Subsidy by endorsement Patient has type 1 diabetes and has had one or more episodes of ketoacidosis (excluding first presentation). Maximum quantity of 2 packs per annum. No further prescriptions will be subsidised. The prescription must be endorsed accordingly. Test strip – Not on a BSO .......................................................... 8.50 10 strip OP ✔ Optium Blood Ketone Test Strips METOPROLOL SUCCINATE Additional subsidy by endorsement for Betaloc CR is available for patients who: 1) were being prescribed metoprolol succinate prior to 1 October 2007; or 2) have experienced a myocardial infarction; or 3) have experienced heart failure and are either intolerant of carvedilol or it is contra-indicated. Pharmacists may annotate prescriptions for patients who were being prescribed metoprolol succinate prior to 1 October 2007 in which case the prescription is deemed to be endorsed. The pharmacist must be able to show a clear documented dispensing history for the patient. The prescription must be endorsed accordingly. continued...

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2009 (continued)

continued... ❋ Tab long-acting 23.75 mg – Higher subsidy of up to $6.20 per 30 with Endorsement ............................................................. 3.61 ❋ Tab long-acting 47.5 mg – Higher subsidy of up to $7.80 per 30 with Endorsement ............................................................. 4.50 ❋ Tab long-acting 95 mg – Higher subsidy of up to $13.20 per 30 with Endorsement ............................................................. 7.40 ❋ Tab long-acting 190 mg – Higher subsidy of up to $21.00 per 30 with Endorsement ........................................................... 12.50 30 30 30 30 ✔ Betaloc CR ✔ Betaloc CR ✔ Betaloc CR ✔ Betaloc CR

NICOTINE – Only on a Quitcard a) Maximum of 28 patch per dispensing b) Maximum of 56 patch per prescription c) For the avoidance of doubt Nicotine will not be funded Close Control in amounts less than 4 weeks. Patch 7 mg ............................................................................ 10.53 7 OP ✔ Habitrol Patch 14 mg .......................................................................... 11.63 7 OP ✔ Habitrol Patch 21 mg .......................................................................... 12.32 7 OP ✔ Habitrol NICOTINE – Only on a Quitcard a) Maximum of 216 loz per dispensing b) Maximum of 432 loz per prescription c) For the avoidance of doubt Nicotine will not be funded Close Control in amounts less than 4 weeks. Lozenge 1 mg ........................................................................ 11.08 36 OP ✔ Habitrol Lozenge 2 mg ........................................................................ 11.08 36 OP ✔ Habitrol NICOTINE – Only on a Quitcard a) Maximum of 384 piece per dispensing b) Maximum of 768 piece per prescription c) For the avoidance of doubt Nicotine will not be funded Close Control in amounts less than 4 weeks. Gum 2 mg (Fruit) .................................................................... 14.97 96 OP ✔ Habitrol 23.41 ✔ Nicotinell Gum 2 mg (Mint) .................................................................... 14.97 96 OP ✔ Habitrol 23.41 ✔ Nicotinell Gum 4 mg (Fruit) .................................................................... 20.02 96 OP ✔ Habitrol 23.41 ✔ Nicotinell Gum 4 mg (Mint) .................................................................... 20.02 96 OP ✔ Habitrol 23.41 ✔ Nicotinell GOSERELIN ACETATE – Special Authority see SA0839 – Hospital pharmacy [HP3] Inj 3.6 mg ............................................................................. 221.60 1 ✔ Zoladex Inj 10.8 mg .......................................................................... 554.70 1 ✔ Zoladex ➽ SA0839 Special Authority for Subsidy Initial application — (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer. Initial application — (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Advanced prostatic cancer; or 2 Neoadjuvant or adjuvant treatment of locally advanced prostatic cancer. Note: Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiated. Initial application — (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: continued...

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2009 (continued)

continued... 1 Endometriosis; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. Note: The maximum treatment period for a GnRH analogue is: • 3 months to assess whether surgery is appropriate • 3 months for infertile patients after surgery • 6 months for patients with symptoms of endometriosis After the first 3 months patients should be assessed to determine whether there has been a satisfactory response to the first 3 months treatment. Initial application — (Precocious puberty) only from a paediatrician or endocrinologist. Approvals valid for 1 year where the patient is affected by gonadotropin dependent precocious puberty. Renewal — (Breast or prostate cancer) from any medical practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment. Note: If a patient had an approval for any GnRH analogue prior to 1 July 2006 the applicant is required to submit a fresh initial application, not a renewal application. Renewal — (Endometriosis) from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: Either: 1 Both: 1.1 There has been a satisfactory response to the first 3 months treatment; and 1.2 Surgery is inappropriate; or 2 The first three months of therapy did not follow surgery for infertility. Note: If a patient had an approval for any GnRH analogue prior to 1 July 2006 the applicant is required to submit a fresh initial application, not a renewal application. Renewal — (Precocious puberty) only from a paediatrician or endocrinologist. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment. Note: If a patient had an approval for any GnRH analogue prior to 1 July 2006 the applicant is required to submit a fresh initial application, not a renewal application. 83 AZITHROMYCIN – Subsidy by endorsement a) Maximum of 2 tab per prescription; can be waived by Special Authority see SA0964 b) Up to 4 tab available on a PSO c) Subsidised only if prescribed for patients with uncomplicated urethritis or cervicitis proven or presumed to be due to chlamydia trachomatis and their sexual contacts and prescription or PSO is endorsed accordingly; can be waived by Special Authority see SA0964. Tab 500 mg ............................................................................. 5.95 2 OP ✔ Arrow-Azithromycin ENTECAVIR – Special Authority see SA0977 – Retail pharmacy Tab 0.5 mg ........................................................................... 400.00 30 ✔ Baraclude ➽ SA0977 Special Authority for Subsidy Initial application only from a gastroenterologist or infectious disease specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and 2 Patient is Hepatitis B nucleoside analogue treatment-naive; and 3 Entecavir dose 0.5 mg/day; and 4 Either: 4.1 ALT greater than upper limit of normal; or 4.2 Bridging fibrosis or cirrhosis (Metavir stage 3 or greater) on liver histology; and 5 Either: continued...

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2009 (continued)

continued... 5.1 HBeAg positive; or 5.2 patient has ≥ 2,000 IU HBV DNA units per ml and fibrosis (Metavir stage 2 or greater) on liver histology; and 6 No continuing alcohol abuse or intravenous drug use; and 7 Not co-infected with HCV, HIV or HDV; and 8 Neither ALT nor AST greater than 10 times upper limit of normal; and 9 No history of hypersensitivity to entecavir; and 10 No previous documented lamivudine resistance (either clinical or genotypic). Notes: • Entecavir should be continued for 6 months following documentation of complete HBeAg seroconversion (defined as loss of HBeAg plus appearance of anti-HBe plus loss of serum HBV DNA) for patients who were HBeAg positive prior to commencing this agent. This period of consolidation therapy should be extended to 12 months in patients with advanced fibrosis (Metavir Stage F3 or F4). • Entecavir should be taken on an empty stomach to improve absorption. TRANYLCYPROMINE SULPHATE Tab 10 mg ............................................................................. 22.94 Note – removal of Section 29 annotation 50 ✔ Parnate S29 S29

112

143

ANASTROZOLE-DP – Subsidy by endorsement Subsidised only for patients with hormone receptor positive advanced breast cancer and the prescription is endorsed accordingly. Tab 1 mg ............................................................................... 29.50 30 ✔ DP-Anastrozole CYCLOSPORIN A – Special Authority see SA0470 – Hospital pharmacy [HP3] Cap 25 mg ............................................................................. 85.00 50 ✔ Neoral Cap 50 mg ........................................................................... 169.34 50 ✔ Neoral Cap 100 mg ......................................................................... 338.69 50 ✔ Neoral Oral liq 100 mg per ml .......................................................... 377.38 50 ml OP ✔ Neoral ➽ SA0470 Special Authority for Subsidy Initial application — (Organ transplant) only from a relevant specialist. Approvals valid without further renewal unless notified where the patient is an organ transplant recipient. Initial application — (Bone marrow transplant or Graft v host disease) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Bone marrow transplant; or 2 Graft v host disease. Initial application — (Psoriasis) only from a dermatologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Psoriasis; and 2 Applicant must state which systemic and topical therapies have failed. Initial application — (Severe atopic dermatitis) only from a dermatologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Severe atopic dermatitis; and 2 Not responsive to topical therapy, oral antihistamines and other commonly used orthodox therapies. Initial application — (Nephrotic Syndrome) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Nephrotic Syndrome; and continued...

147

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

S29

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2009 (continued)

continued... 2 Corticosteroid dependent patients who have failed on cytotoxic therapy. Initial application — (Endogenous uveitis) only from a relevant specialist. Approvals valid for 2 years where the patient suffers from endogenous uveitis. Initial application — (Severe rheumatoid arthritis) only from a rheumatologist. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Severe rheumatoid arthritis; and 2 The patient must be either unresponsive to or unable to tolerate, both sulphasalazine and methotrexate; and 3 Patients must have 2 serum creatinine test results within the normal range within the three months prior to initiation of therapy. Renewal — (Severe atopic dermatitis) only from a dermatologist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal — (Indications other than severe atopic dermatitis) only from a dermatologist, rheumatologist or relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. Guidelines for use of cyclosporin A in rheumatoid arthritis Monitoring: All patients require frequent monitoring for creatinine levels and blood pressure: • fortnightly, in the first three months of therapy and then monthly, if results are stable; • if dose is increased or there is a rise in serum creatinine or blood pressure, then more frequent monitoring is required. Contraindications: Cyclosporin A is contraindicated in patients with the following conditions: • current or past malignancy; • uncontrolled hypertension; • renal dysfunction (abnormal serum creatinine for age and sex); • immunodeficiency and neutropenia; • abnormally low white blood cell count or platelet count; or • liver function tests more than twice the upper limit of normal. Caution in use: • age above 65 years; • controlled hypertension; • use of anti-epileptic medications; • use of ketoconazole, fluconazole, trimethoprim, erythromycin, verapamil, and diltiazem; • concurrent or previous use of alkylating agents such as cyclophosphamide; • use of any experimental drug within the past three months; • premalignant conditions such as leukoplakia, monoclonal paraproteinaemia, myelodysplastic syndrome and dysplastic naevi; • active infection may necessitate temporary discontinuation; • pregnancy and lactation. Therapy should be discontinued if there has been no improvement after 6 months with the patient on the maximum tolerated dose. For further information please consult the data sheet. 166 PILOCARPINE ORAL LIQUID Pilocarpine 4% 6% eye drops qs Preservative qs Water to 500 ml (Preservative should be used if quantity supplied is for more than 5 days.)

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price

Effective 1 October 2009

26 27 30 HYDROCORTISONE ACETATE ( subsidy) Rectal foam 10 %, CFC-Free (14 applications) ........................ 23.00 ATROPINE SULPHATE ( subsidy) ❋ Inj 600 μg, 1 ml – Up to 5 inj available on a PSO...................... 52.00 21.1 g OP ✔ Colifoam 50 ✔ AstraZeneca

PIOGLITAZONE – Special Authority see SA0959 – Retail pharmacy ( subsidy) Tab 15 mg ............................................................................... 2.61 28 (45.78) Tab 30 mg ............................................................................... 5.23 28 (70.43) Tab 45 mg ............................................................................... 7.80 28 (89.39)

Actos Actos Actos

BLOOD GLUCOSE DIAGNOSTIC TEST STRIP ( subsidy) The number of test strips available on a prescription is restricted to 50 unless: 1) Prescribed with insulin or a sulphonylurea but are on a different prescription and the prescription is endorsed accordingly; or 2) Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; or 3) Prescribed for a pregnant woman with diabetes and endorsed accordingly. Blood glucose test strips ........................................................ 21.65 50 test OP ✔ Accu-Chek Performa VITAMIN A WITH VITAMINS D AND C ( subsidy and  price) Soln 1000 u with Vitamin D 400 u and ascorbic acid 30 mg per 10 drops ......................................................................... 4.50 HEPARIN SODIUM ( subsidy) Inj 5,000 iu per ml, 1 ml ......................................................... 14.20 POTASSIUM CHLORIDE ( subsidy) ❋ Tab long-acting 600 mg ........................................................... 7.00 CLONIDINE ( subsidy) ❋ TDDS 2.5 mg, 100 μg per day – Only on a prescription............ 23.30 ❋ TDDS 5 mg, 200 μg per day – Only on a prescription............... 32.80 ❋ TDDS 7.5 mg, 300 μg per day – Only on a prescription............ 41.20 CLONIDINE HYDROCHLORIDE ( subsidy) ❋ Tab 150 µg ............................................................................ 33.00 ❋ Inj 150 μg per ml, 1 ml ........................................................... 15.45 CALAMINE ( subsidy) a) Only on a prescription b) Not in combination Crm, aqueous, BP .................................................................... 2.78 (3.02) Lotn, BP ................................................................................. 16.70 (19.44)

10 ml OP 5 200 4 4 4 100 5

✔ Vitadol C ✔ Mayne ✔ Span-K ✔ Catapres-TTS-1 ✔ Catapres-TTS-2 ✔ Catapres-TTS-3 ✔ Catapres ✔ Catapres

42 44 54

100 g ABM 2,000 ml ABM

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer's Price – effective 1 October 2009 (continued)

61 CLOBETASOL PROPIONATE ( subsidy) ❋ Crm 0.05% ............................................................................... 3.48 ❋ Oint 0.05% ............................................................................... 3.48 WOOL FAT WITH MINERAL OIL – Only on a prescription ( price) ❋ Lotn hydrous 3% with mineral oil .............................................. 5.60 (20.53) BETAMETHASONE VALERATE ( subsidy) ❋ Scalp app 0.1% ........................................................................ 7.22 CLOBETASOL PROPIONATE ( subsidy) ❋ Scalp app 0.05% ...................................................................... 6.36 OXYTOCIN – Up to 5 inj available on a PSO ( subsidy) Inj 5 iu per ml, 1 ml .................................................................. 5.94 Inj 10 iu per ml, 1 ml ................................................................ 7.48 Inj 5 iu with ergometrine maleate 500 μg per ml, 1 ml ............. 10.12 HYDROCORTISONE ( subsidy) ❋ Tab 5 mg ................................................................................. 8.35 ❋ Tab 20 mg ............................................................................. 20.95 30 g OP 30 g OP 1,000 ml Alpha-Keri Lotion 100 ml OP ✔ Beta Scalp 30 ml OP 5 5 5 100 100 ✔ Dermol ✔ Syntocinon ✔ Syntocinon ✔ Syntometrine ✔ Douglas ✔ Douglas ✔ Dermol ✔ Dermol

66 66 73

75 82

METHYLPREDNISOLONE SODIUM SUCCINATE – Retail pharmacy-Specialist ( subsidy) Inj 500 mg ............................................................................. 20.80 1 ✔ Solu-Medrol LEUPRORELIN – Hospital pharmacy [HP3] ( subsidy) Inj 7.5 mg ............................................................................ 166.20 Inj 22.5 mg .......................................................................... 443.76 Inj 30 mg ............................................................................. 591.68 Inj 45 mg ............................................................................. 832.05 FLUCLOXACILLIN SODIUM ( subsidy) Grans for oral liq 125 mg per 5 ml – Up to 200 ml available on a PSO ............................................................................... 3.12 Grans for oral liq 250 mg per 5 ml – Up to 200 ml available on a PSO ............................................................................... 3.55 1 1 1 1 ✔ Eligard ✔ Eligard ✔ Eligard ✔ Eligard

100 ml 100 ml

✔ AFT ✔ AFT

GENTAMICIN SULPHATE ( subsidy) Inj 40 mg per ml, 2 ml – Hospital pharmacy [HP3] – Subsidy by endorsement ..................................................................... 9.00 10 ✔ Pfizer Only if prescribed for a dialysis or cystic fibrosis patient or for prophylaxis of endocarditis and the prescription is endorsed accordingly. NAPROXEN ( subsidy) ❋ Tab 250 mg ........................................................................... 23.70 ❋ Tab 500 mg ........................................................................... 24.88 BACLOFEN ( subsidy) ❋ Tab 10 mg ............................................................................... 4.75 500 250 100 ✔ Noflam 250 ✔ Noflam 500 ✔ Pacifen

100

107

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer's Price – effective 1 October 2009 (continued)

107 QUININE SULPHATE ( subsidy) ❋ Tab 300 mg ........................................................................... 54.06 ‡ Safety cap for extemporaneously compounded oral liquid preparations. MORPHINE HYDROCHLORIDE ( subsidy) a) Only on a controlled drug form b) No patient co-payment payable ‡ Oral liq 1 mg per ml .................................................................. 8.84 ‡ Oral liq 2 mg per ml ................................................................ 11.62 ‡ Oral liq 5 mg per ml ................................................................ 14.65 ‡ Oral liq 10 mg per ml .............................................................. 21.55 MORPHINE SULPHATE ( subsidy) a) Only on a controlled drug form b) No patient co-payment payable Tab immediate-release 10 mg ................................................... 2.80 Tab immediate-release 20 mg ................................................... 5.52 500 ✔ Q 300

110

200 ml 200 ml 200 ml 200 ml

✔ RA-Morph ✔ RA-Morph ✔ RA-Morph ✔ RA-Morph

110

10 10

✔ Sevredol ✔ Sevredol

112

MOCLOBEMIDE ( subsidy) Note: There is a significant cost differential between moclobemide and fluoxetine (moclobemide being about three times more expensive). For depressive syndromes it is therefore more cost-effective to start treatment with fluoxetine first before considering prescribing moclobemide. Tab 150 mg ........................................................................... 69.23 500 ✔ Apo-Moclobemide Tab 300 mg ........................................................................... 31.33 100 ✔ Apo-Moclobemide CLONIDINE HYDROCHLORIDE ( subsidy) ❋ Tab 25 µg .............................................................................. 19.25 LEVODOPA WITH CARBIDOPA ( subsidy) ❋ Tab long-acting 200 mg with carbidopa 50 mg ....................... 47.50 ❋ Tab 250 mg with carbidopa 25 mg ......................................... 40.00 CARBOPLATIN – PCT only – Specialist Inj 10 mg per ml, 5 ml ( subsidy) ........................................... 20.00 Inj 10 mg per ml, 15 ml ( subsidy) ......................................... 22.50 Inj 10 mg per ml, 45 ml ( subsidy) ......................................... 55.00 Inj 10 mg per ml, 100 ml ( subsidy) ..................................... 120.00 Inj 1 mg for ECP ( subsidy) ...................................................... 0.15 SODIUM CROMOGLYCATE ( subsidy) Nasal spray, 4% ..................................................................... 15.85 DORZOLAMIDE HYDROCHLORIDE WITH TIMOLOL MALEATE ( subsidy) ❋ Eye drops 2% with timolol maleate 0.5% ................................. 15.50 100 100 100 1 1 1 1 1 mg 22 ml OP 5 ml OP ✔ Dixarit ✔ Sinemet CR ✔ Sinemet ✔ Carboplatin Ebewe ✔ Carboplatin Ebewe ✔ Carboplatin Ebewe ✔ Carboplatin Ebewe ✔ Baxter ✔ Rex ✔ Cosopt

117 119

134

155 159

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer's Price – effective 1 September 2009

32 40 INSULIN PEN NEEDLES – Maximum of 100 dev per prescription ( subsidy) ❋ 31 g × 5 mm ......................................................................... 11.75 100 ✔ B-D Micro-Fine ✔ Apo-Clopidogrel Plavix ✔ Betaloc CR ✔ Betaloc CR ✔ Betaloc CR ✔ Betaloc CR

CLOPIDOGREL – Special Authority see SA0867 – Retail pharmacy ( subsidy) Tab 75 mg ............................................................................. 25.00 28 (73.38) METOPROLOL SUCCINATE ( subsidy) ❋ Tab long-acting 23.75 mg ......................................................... 3.61 ❋ Tab long-acting 47.5 mg ........................................................... 4.50 ❋ Tab long-acting 95 mg .............................................................. 7.40 ❋ Tab long-acting 190 mg .......................................................... 12.50 POVIDONE IODINE ( subsidy) Skin preparation, povidone iodine 10% with 30% alcohol ....................................................................... 10.00 DANAZOL – Retail pharmacy-Specialist ( subsidy) Cap 100 mg ........................................................................... 20.50 68.33 Cap 200 mg ........................................................................... 29.35 BETAHISTINE DIHYDROCHLORIDE ( subsidy) ❋ Tab 16 mg ............................................................................... 9.26 30 30 30 30

500 ml 30 100 30 84

✔ Betadine Skin Prep ✔ D-Zol ✔ Azol ✔ D-Zol ✔ Vergo 16 ✔ Baxter ✔ Flutamin

117 141 143 155

VINORELBINE – PCT only – Specialist – Special Authority see SA0901 ( subsidy) Inj 1 mg for ECP ....................................................................... 2.71 1 mg FLUTAMIDE – Hospital pharmacy [HP3]-Specialist ( subsidy) Tab 250 mg ........................................................................... 48.30 100

BUDESONIDE ( price) Metered aqueous nasal spray, 50 μg per dose .......................... 2.35 200 dose OP (4.00) Metered aqueous nasal spray, 100 μg per dose ........................ 2.61 200 dose OP (4.81) FLUOROMETHOLONE ( subsidy) ❋ Eye drops 0.1% ........................................................................ 4.05 (4.30) 5 ml OP

Butacort Aqueous Butacort Aqueous

158

Flucon

175

ORAL FEED 1KCAL/ML – Special Authority see SA0589 – Hospital pharmacy [HP3] ( subsidy) Liquid ........................................................................................ 1.90 200 ml OP ✔ Fortimel

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Brand Name

Effective 1 October 2009

137 AMSACRINE – PCT only – Specialist Inj 75 mg ............................................................................. CBS 6 ✔ Amsidine Amsidyl

S29

Changes to Sole Subsidised Supply

Effective 1 October 2009

For the list of new Sole Subsidised Supply products effective 1 October 2009 refer to the bold entries in the cumulative Sole Subsidised Supply table pages 10-16.

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items

Effective 1 October 2009

48 TERAZOSIN HYDROCHLORIDE ❋ Tab 2 mg .................................................................................. 1.30 ❋ Tab 5 mg .................................................................................. 1.62 CILAZAPRIL Tab 2.5 mg ............................................................................... 4.39 Tab 5 mg .................................................................................. 6.44 INDOMETHACIN ❋ Cap 50 mg ................................................................................ 6.95 APOMORPHINE HYDROCHLORIDE ▲ Inj 10 mg per ml, 2 ml ............................................................. 50.43 ▲ Inj 10 mg per ml, 1 ml ............................................................. 50.53 AZATHIOPRINE – Retail pharmacy – Specialist ❋ Tab 50 mg .............................................................................. 25.00 28 28 30 30 100 5 5 100 ✔ Hytrin ✔ Hytrin ✔ Inhibace ✔ Inhibace ✔ Rheumacin ✔ APO-go S29 ✔ Mayne ✔ Thioprine

100 119

145 170

CARBOHYDRATE SUPPLEMENT – Special Authority – Hospital pharmacy [HP3] Powder ..................................................................................... 1.14 350 g OP (7.85)

Polycose

176

PAEDIATRIC ORAL FEED 1KCAL/ML – Special Authority – Hospital pharmacy [HP3] Liquid (strawberry) .................................................................... 1.27 237 ml OP ✔ Pediasure Liquid (chocolate) ..................................................................... 1.27 237 ml OP ✔ Pediasure

Effective 1 September 2009

32 BLOOD GLUCOSE DIAGNOSTIC TEST STRIP The number of test strips available on a prescription is restricted to 50 unless: 1) Prescribed with insulin or a sulphonylurea but are on a different prescription and the prescription is endorsed accordingly; or 2) Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; or 3) Prescribed for a pregnant woman with diabetes and endorsed accordingly. Blood glucose test strips ........................................................ 22.00 50 test OP ✔ Optium 10 second test 11.00 25 test OP ✔ Optium 10 second test GLYCEROL ❋ Suppos 2.55 g – Only on a prescription .................................... 3.12 LABETALOL ❋ Inj 5 mg per ml, 5 ml .............................................................. 14.77 (22.15) 12 ✔ Fleet Glycerin Suppositories

Trandate S29

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items – effective 1 September 2009 (continued)

62 TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN AND NYSTATIN Oint 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 μg per g – Only on a prescription............. 3.00 15 g OP ETHINYLOESTRADIOL WITH GESTODENE ❋ Tab 30 μg with gestodene 75 μg and 7 inert tab ....................... 6.62 84 (14.49) a) Higher subsidy of $14.49 per 84 with Special Authority see SA0500 above b) Up to 84 tab available on a PSO

✔ Kenacomb

Minulet 28

ETHINYLOESTRADIOL WITH LEVONORGESTREL ❋ Tab ethinyloestradiol 30 μg with levonorgestrel 50 μg (6) and tab ethinyloestradiol 40 μg with levonorgestrel 75 μg (5), and tab ethinyloestradiol 30 μg with levonorgestrel 125 μg (10) and 7 inert tab ............................................................... 6.62 84 (14.49) Triphasil 28 a) Higher subsidy of up to $14.49 per 84 with Special Authority see SA0500 on the preceding page b) Up to 84 tab available on a PSO TRIAMCINOLONE ACETONIDE Inj 10 mg per ml, 5 ml ............................................................ 10.31 DICLOXACILLIN Cap 250 mg ............................................................................. 2.47 (4.35) Cap 500 mg ............................................................................. 3.83 (8.65) ROPINIROLE HYDROCHLORIDE ▲ Tab 0.25 mg .......................................................................... 19.75 (31.50) ▲ Tab 0.25 mg × 42, 0.5 mg × 42 and 1 mg × 21 .................. 21.92 (35.70) ▲ Tab 0.5 mg × 42, 1 mg × 42 and 2 mg × 63 ....................... 73.60 (122.11) ▲ Tab 1 mg ............................................................................... 40.32 (67.20) ▲ Tab 2 mg ............................................................................... 60.72 (101.21) ▲ Tab 5 mg ............................................................................... 90.00 (150.00) 1 24 Diclocil 24 Diclocil 210 Requip 105 Requip Starter Pack 147 Requip Follow-on Pack 84 Requip 84 Requip 84 Requip ✔ Kenacort-A

76 85

120

174

DIABETIC ENTERAL FEED 1KCAL/ML – Special Authority see SA0594 – Hospital pharmacy [HP3] Liquid ........................................................................................ 7.50 1,000 ml OP ✔ Resource Diabetic TF RTH

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted

Effective 1 December 2009

158 FLUOROMETHOLONE ❋ Eye drops 0.1% ........................................................................ 4.05 (4.30) 5 ml OP Flucon

Effective 1 January 2010

60 CALAMINE a) Only on a prescription b) Not in combination Crm, aqueous, BP .................................................................... 2.78 (3.02) Lotn, BP ................................................................................. 16.70 (19.44)

100 g ABM 2,000 ml ABM

Effective 1 March 2010

97 PEGYLATED INTERFERON ALPHA-2B WITH RIBAVIRIN – Special Authority see SA0953 – Hospital pharmacy [HP3] See prescribing guideline Inj 50 μg × 4 with ribavirin cap 200 mg × 112 ................. 1,080.40 1 OP ✔ Pegatron Combination Therapy Inj 50 μg × 4 with ribavirin cap 200 mg × 84 ...................... 976.80 1 OP ✔ Pegatron Combination Therapy Inj 80 μg × 4 with ribavirin cap 200 mg × 140 ................. 1,583.60 1 OP ✔ Pegatron Combination Therapy Inj 80 μg × 4 with ribavirin cap 200 mg × 168 ................. 1,687.20 1 OP ✔ Pegatron Combination Therapy Inj 80 μg × 4 with ribavirin cap 200 mg × 84 ................... 1,376.40 1 OP ✔ Pegatron Combination Therapy Inj 100 μg × 4 with ribavirin cap 200 mg × 112 ............... 1,746.40 1 OP ✔ Pegatron Combination Therapy Inj 100 μg × 4 with ribavirin cap 200 mg × 84 ................. 1,642.80 1 OP ✔ Pegatron Combination Therapy Inj 120 μg × 4 with ribavirin cap 200 mg × 140 ............... 2,116.40 1 OP ✔ Pegatron Combination Therapy Inj 120 μg × 4 with ribavirin cap 200 mg × 84 ................. 1,909.20 1 OP ✔ Pegatron Combination Therapy Inj 150 μg × 4 with ribavirin cap 200 mg × 140 ............... 2,516.00 1 OP ✔ Pegatron Combination Therapy continued... Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber. ❋ Three months or six months, as applicable, dispensed all-at-once

▲

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted – effective 1 March 2010 (continued)

continued... Inj 150 μg × 4 with ribavirin cap 200 mg × 168 ............... 2,619.60 Inj 150 μg × 4 with ribavirin cap 200 mg × 84 ................. 2,308.80

1 OP 1 OP

✔ Pegatron Combination Therapy ✔ Pegatron Combination Therapy ✔ Tripress ✔ Mogine ✔ Alpha-Bromocriptine ✔ Pro-Pam

112 115 119 125

TRIMIPRAMINE MALEATE Cap 25 mg ............................................................................... 6.20 LAMOTRIGINE ▲ Tab dispersible 200 mg ........................................................ 101.80 BROMOCRIPTINE MESYLATE ❋ Tab 10 mg ........................................................................... 120.86 DIAZEPAM Tab 5 mg – Month Restriction.................................................... 5.00 ‡ Safety cap for extemporaneously compounded oral liquid preparations. PACLITAXEL – PCT only – Specialist Inj 30 mg ............................................................................... 37.95 Note – Paclitaxel Ebewe inj 30 mg, 5 inj pack remains listed. PILOCARPINE ❋ Eye drops 1% ........................................................................... 3.24

100 56 100 250

140

✔ Paclitaxel Ebewe

160 183

15 ml OP

✔ Pilopt

GLUTEN FREE PASTA – Special Authority see SA0722 – Hospital pharmacy [HP3] Corn and Spinach Rigatini.......................................................... 2.00 250 g OP (2.92) Garlic and Parsley Shells ........................................................... 2.00 250 g OP (2.92) Rice and Corn Garden Herb Pasta .............................................. 2.00 250 g OP (2.92)

Orgran Orgran Orgran

Effective 1 April 2010

40 42 125 PHYTOMENADIONE Tab 10 mg ............................................................................... 5.60 HEPARINISED SALINE ❋ Inj 10 iu per ml, 5 ml .............................................................. 18.00 DIAZEPAM Tab 10 mg – Month Restriction.................................................. 3.45 ‡ Safety cap for extemporaneously compounded oral liquid preparations. PILOCARPINE ❋ Eye drops 4% ............................................................................ 6.57 10 50 100 ✔ Konakion ✔ AstraZeneca ✔ Pro-Pam

160 178

15 ml OP

✔ Pilopt

SEMI-ELEMENTAL ENTERAL FEED 1KCAL/ML - Special Authority – Hospital pharmacy [HP3] Liquid ........................................................................................ 6.02 500 ml OP ✔ Peptisorb

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes to Part II

Effective 1 October 2009

ALENDRONATE SODIUM Tab 40 mg......................................Fosamax ALENDRONATE SODIUM WITH CHOLECALCIFEROL Tab 70 mg with cholecalciferol 5,600 iu .....................................Fosamax Plus APREPITANT Cap 2 x 80 mg and 1 x 125 mg.......Emend Tri-Pack ATROPINE SULPHATE ( price and addition of HSS) Inj 600 μg, 1 ml..............................AstraZeneca BACLOFEN ( price and addition of HSS) Tab 10 mg......................................Pacifen 133.00 30

35.91 116.00

4 3

52.00 4.75

50 100 100 ml 1 1 1

1% 1% 1%

Dec-09 Dec-09 Dec-09

(B) Alpha-Baclofen (B)

BETAMETHASONE VALERATE ( price and addition of HSS) Scalp app 0.1% .............................Beta Scalp 7.22 BLOOD GLUCOSE DIAGNOSTIC TEST METER Meter .............................................CareSens II CareSens POP Accu-Chek Performa BLOOD GLUCOSE DIAGNOSTIC TEST STRIP Blood glucose test strips.................Accu-Chek Performa Blood glucose test strips x 50 and lancets x 5 .................................CareSens CARBOPLATIN (addition of HSS) Inj 10 mg per ml, 5 ml ( price) ......Carboplatin Ebewe Inj 10 mg per ml, 15 ml ( price) ....Carboplatin Ebewe Inj 10 mg per ml, 45 ml ( price) ....Carboplatin Ebewe Inj 10 mg per ml, 100 ml ( price) ..Carboplatin Ebewe 9.00 6.00 19.00

21.65 19.60 20.00 22.50 55.00 120.00

50 1 1 1 1 1 1% 1% 1% 1% Dec-09 Dec-09 Dec-09 Dec-09 Hospira Pfizer Hospira Pfizer Hospira Pfizer Hospira Pfizer (B) (B) Clobex Shampoo

CLOBETASOL PROPIONATE ( price and addition of HSS) Crm 0.05% ....................................Dermol 3.48 CLOBETASOL PROPIONATE Oint 0.05% ....................................Dermol Scalp app 0.05% ............................Dermol 3.48 6.36

30 g 30 g 30 ml

1% 1% 1%

Dec-09 Dec-09 Dec-09

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes to Part II - effective 1 October 2009 (continued)

CLONIDINE ( price and addition of HSS) TDDS 2.5 mg, 100 μg per day ........Catapres-TTS-1 TDDS 5 mg, 200 μg per day ...........Catapres-TTS-2 TDDS 7.5 mg, 300 μg per day ........Catapres-TTS-3 CLONIDINE HYDROCHLORIDE Tab 25 µg ......................................Dixarit 23.30 32.80 41.20 19.25 4 4 4 100 1% 1% 1% 1% Dec-09 Dec-09 Dec-09 Dec-09 Dec-09 Dec-09 (B) (B) (B) (B) (B) (B)

CLONIDINE HYDROCHLORIDE (amended description,  price and addition of HSS) Inj 150 μg per ml, 1 ml ...................Catapres 15.45 5 1% Tab 150 µg ....................................Catapres 33.00 100 1% DIAZEPAM Tab 10 mg......................................Pro-Pam 3.45 Note – Pro-Pam tab 10 mg to be delisted 1 December 2009 DORZOLAMIDE HYDROCHLORIDE WITH TIMOLOL MALEATE Eye drops 2% with timolol maleate 0.5% .............................Cosopt 15.50 100

5 ml

FLUCLOXACILLIN SODIUM (amended description,  price and addition of HSS) Grans for oral liq 125 mg per 5 ml ........................AFT 3.12 100 ml Grans for oral liq 250 mg per 5 ml ........................AFT 3.55 100 ml FLUTICASONE Aerosol inhaler, 50 μg per dose CFC-free ....................................Flixotide Aerosol inhaler, 125 μg per dose CFC-free ....................................Flixotide Aerosol inhaler, 250 μg per dose CFC-free ....................................Flixotide Powder for inhalation, 50 μg per dose ....................................Flixotide Accuhaler Powder for inhalation, 100 μg per dose ....................................Flixotide Accuhaler Powder for inhalation, 250 μg per dose ....................................Flixotide Accuhaler GENTAMICIN SULPHATE ( price and addition of HSS) Inj 40 mg per ml, 2 ml ...................Pfizer GLYCERYL TRINITRATE ( price and addition of HSS) Inj 1 mg per ml, 5 ml ......................Nitronal Inj 1 mg per ml, 50 ml ....................Nitronal

1% 1%

Dec-09 Dec-09

(B) (B)

7.50 13.60 27.20 8.67 13.87 24.51

120 dose 120 dose 120 dose 60 dose 60 dose 60 dose

9.00 22.70 86.60

10 10 10

1% 1% 1%

Dec-09 Dec-09 Dec-09

Hospira (B) (B)

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes to Part II - effective 1 October 2009 (continued)

HEPARIN SODIUM Inj 1,000 iu per ml, 5 ml .................Pfizer Inj 5,000 iu per ml, 5 ml .................Pfizer HEPARINISED SALINE Inj 10 iu per ml, 5 ml ......................Pfizer 11.44 46.30 118.50 32.50 10 50 50 50

HEPARINISED SALINE Inj 10 iu per ml, 5 ml ......................AstraZeneca 18.00 50 Note – AstraZeneca’s brand of heparinised saline inj 10 iu per ml, 5 ml to be delisted 1 December 2009 HYDROCORTISONE ( price and addition of HSS) Tab 5 mg........................................Douglas Tab 20 mg......................................Douglas 8.35 20.95 100 100 1% 1% Dec-09 Dec-09 (B) (B)

HYDROCORTISONE ACETATE ( price and addition of HSS) Rectal foam 10%, CFC-Free (14 applications) .......................Colifoam 23.00

21.1 g

Dec-09

(B)

HYDROXYETHYL STARCH 200/0.5 PENTASTARCH (amended description,  price and addition of HSS) Inj Inf 6%, 500 ml bag ....................StarQuin 200 296.00 16 1% Dec-09 HAES-steril 6% 6% LEUPRORELIN ( price) Inj 7.5 mg.......................................Eligard Inj 22.5 mg.....................................Eligard Inj 30 mg........................................Eligard Inj 45 mg........................................Eligard LEVODOPA WITH CARBIDOPA Tab 100 mg with carbidopa 25 mg .Sinemet Tab 250 mg with carbidopa 25 mg .Sinemet Tab long-acting 200 mg with carbidopa 50 mg........................Sinemet CR 166.20 443.76 591.68 832.05 20.00 40.00 47.50 1 1 1 1 100 100 100 25 25 1 1 500 100 1% 1% 1% 1% 1% 1% Dec-09 Dec-09 Dec-09 Dec-09 Dec-09 Dec-09 (B) (B) Hospira Hospira (B) (B)

METHYLPREDNISOLONE SODIUM SUCCINATE (addition of HSS) Inj 40 mg per ml, 1 ml ....................Solu-Medrol 151.40 Inj 62.5 mg per ml, 2 ml .................Solu-Medrol 412.59 Inj 500 mg ( price)........................Solu-Medrol 20.80 Inj 1 g.............................................Solu-Medrol 42.57 MOCLOBEMIDE Tab 150 mg....................................ApoMoclobemide Tab 300 mg....................................ApoMoclobemide 69.23 31.33

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes to Part II - effective 1 October 2009 (continued)

MORPHINE HYDROCHLORIDE ( price and addition of HSS) Oral liq 1 mg per ml ........................RA-Morph 8.84 Oral liq 2 mg per ml ........................RA-Morph 11.62 Oral liq 5 mg per ml ........................RA-Morph 14.65 Oral liq 10 mg per ml ......................RA-Morph 21.55 MORPHINE SULPHATE ( price and addition of HSS) Tab immediate release 10 mg .........Sevredol Tab immediate release 20 mg .........Sevredol NAPROXEN Tab 250 mg....................................Noflam 250 Tab 500 mg....................................Noflam 500 OXYTOCIN ( price and addition of HSS) Inj 5 iu per ml, 1 ml ........................Syntocinon Inj 10 iu per ml, 1 ml ......................Syntocinon 2.80 5.52 23.70 24.88 5.94 7.48 200 ml 200 ml 200 ml 200 ml 10 10 500 250 5 5 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% Dec-09 Dec-09 Dec-09 Dec-09 Dec-09 Dec-09 Dec-09 Dec-09 Dec-09 Dec-09 (B) (B) (B) (B) (B) (B) (B) (B) (B) (B)

OXYTOCIN WITH ERGOMETRINE MALEATE ( price and addition of HSS) Inj 5 iu with ergometrine maleate 500 μg per ml, 1 ml ...................Syntometrine 10.12 5 PANCURONIUM BROMIDE ( price and addition of HSS) Inj 2 mg per ml, 2 ml ......................AstraZeneca 128.00 PHYTOMENADIONE Tab 10 mg......................................Konakion 5.60 Note – Konakion tab 10 mg to be delisted 1 December 2009. POTASSIUM CHLORIDE ( price and addition of HSS) Tab long-acting 600 mg..................Span-K QUININE SULPHATE ( price and addition of HSS) Tab 300 mg....................................Q 300 RALTEGRAVIR POTASSIUM Tab 400 mg....................................Isentress RISPERIDONE Oral liq 1 mg per ml ........................Risperon TIMOLOL MALEATE Eye drops 0.25%, gel forming .........Timoptol XE Eye drops 0.5%, gel forming ...........Timoptol XE 7.00 50 10

1% 1%

Dec-09 Dec-09

(B) (B)

200

Dec-09

Slow-K K-SR Apo-Quinine

54.06 1,350.00 18.35 3.30 3.78

500 60 30 ml 2.5 ml 2.5 ml

Dec-09

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes to Part II - effective 1 September 2009

ACICLOVIR Inj 250 mg 25 mg per ml, 10 ml .....Pfizer 25.50 5 1% Nov-09 Acihexal Hospira Lovir m-Aciclovir Zovirax

Note – Mayne brand of aciclovir inj 250 mg to be delisted 1 November 2009. BACLOFEN Inj 10 mg........................................Lioresal Intrathecal BETAHISTINE DIHYDROCHLORIDE ( price) Tab 16 mg......................................Vergo 16 BLOOD GLUCOSE DIAGNOSTIC TEST METER Meter .............................................Optium Xceed 190.08 1 1% Nov-09 (B)

9.26 9.00

84 1

BUDESONIDE ( price) Metered aqueous nasal spray, 50 μg per dose ..........................Butacort Aqueous 4.00 Metered aqueous nasal spray, 100 μg per dose ........................Butacort Aqueous 4.81 CASPOFUNGIN Inj 50 mg........................................Cancidas Inj 70 mg........................................Cancidas CHLORHEXIDINE Crm 1 % obstetric ...........................healthE 667.50 862.50 1.36

200 doses 200 doses 1 1 50 g 1% 1% 1% Nov-09 Nov-09 Nov-09 (B) (B) Hibitane Orion PSM

Note – Orion brand of chlorhexidine crm 1% obstetric to be delisted 1 November 2009. CLONAZEPAM ( price) Inj 1 mg per ml, 1 ml ......................Rivotril CLOPIDOGREL Tab 75 mg ( price)........................Apo-Clopidogrel Tab 75 mg (new listing) ..................Arrow -Clopidogrel 19.00 25.00 25.00 5 28 28

DANAZOL ( price) Cap 100 mg ...................................D-Zol 20.50 30 Azol 68.33 100 Cap 200 mg ...................................D-Zol 29.35 30 Note – D-Zol brand of danazol cap 100 mg 30 pack size to be delisted 1 October 2009 DIAZEPAM Tab 5 mg........................................Pro-Pam 5.00 Note – Pro-Pam tab 5 mg to be delisted 1 November 2009. Products with Hospital Supply Status (HSS) are in bold. 250

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes to Part II - effective 1 September 2009 (continued)

FLUTAMIDE ( price) Tab 250 mg ...................................Flutamin HYDROXYETHYL STARCH 130/0.4 Inj 6 %............................................Voluven INSULIN PEN NEEDLES 29 g x 12.7 mm..............................SC Profi-Fine 31 g x 5 mm...................................SC Profi-Fine 31 g x 8 mm...................................SC Profi-Fine 48.30 198.00 11.75 11.75 11.75 100 20 100 100 100 1% Nov-09 Venofundin 6%

INSULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE Syringe 0.3 ml with 29 g x 12.7 mm needle ......................DM Ject 13.00 Syringe 0.3 ml with 31 g x 8 mm needle ...........................DM Ject 13.00 Syringe 0.5 ml with 29 g x 12.7 mm needle ......................DM Ject 13.00 Syringe 0.5 ml with 31 g x 8 mm needle ...........................DM Ject 13.00 Syringe 1 ml with 29 g x 12.7 mm needle ......................DM Ject 13.00 Syringe 1 ml with 31 g x 8 mm needle ...........................DM Ject 13.00 ISOTRETINOIN Cap 10 mg .....................................Oratane Cap 20 mg .....................................Oratane 48.48 69.70

100 100 100 100 100 100 180 180 1% 1% Nov-09 Nov-09 Isotane 10 Roaccutane Isotane 20 Roaccutane

Note – Isotane 10 and Isotane 20 to be delisted 1 November 2009. LAMOTRIGINE Tab dispersible 200 mg ..................Mogine 101.80 56 Note – Mogine tab dispersible 200 mg to be delisted 1 November 2009 LIGNOCAINE Gel 2% ...........................................Xylocaine Jelly 6.00 30 ml Note – Orion brand of lignocaine gel 2% to be delisted 1 November 2009. METOPROLOL SUCCINATE Tab long-acting 23.75 mg...............Betaloc CR Tab long-acting 47.5 mg.................Betaloc CR Tab long-acting 95 mg....................Betaloc CR Tab long-acting 190 mg..................Betaloc CR 3.61 4.50 7.40 12.50 30 30 30 30 1% Nov-09 Orion

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes to Part II - effective 1 September 2009 (continued)

ONDANSETRON HYDROCHLORIDE ( price) Inj 2 mg per ml, 2 ml ......................Zofran Hospira Ondansetron Sandoz Onsetron Inj 2 mg per ml, 4 ml ......................Zofran 23.20 5 1% Nov-09 Hospira Ondansetron Sandoz Onsetron Note – The Mayne brand of ondansetron inj 2 mg per ml, 2 ml and 4 ml to be delisted 1 November 2009. Anzatax Taxol Note – Paclitaxel Ebewe inj 30 mg, 1 inj pack, to be delisted 1 November 2009. Please note that the 5 inj pack remains listed. 1 1% Oct-08 14.40 5 1% Nov-09

PACLITAXEL Inj 30 mg........................................Paclitaxel Ebewe 37.95

POVIDONE IODINE Alcohol skin preparation 10% with 30 % alcohol ( price).........Betadine Skin Prep Antiseptic soln 10% ( price) ..........Betadine Oint 10 % ( price) .........................Betadine ZUCLOPENTHIXOL HYDROCHLORIDE Tab 10 mg......................................Clopixol

10.00 6.20 3.27 31.45

500 ml 500 ml 25 g 100

Effective 1 August 2009

ATENOLOL ( price) Tab 50 mg......................................Pacific Atenolol 6.18 500 1% Oct-09 Anselol Apo-Atenolol Atehexal Global Atenolol Anselol Apo-Atenolol Atehexal Global Atenolol

Tab 100 mg ...................................Pacific Atenolol

10.73

500

Oct-09

CLOZAPINE ( price) Oral liq 50 mg per ml ......................Clopine Tab 25 mg......................................Clopine Clopine Tab 50 mg......................................Clopine Clopine Tab 100 mg....................................Clopine Clopine Tab 200 mg....................................Clopine Clopine

17.33 6.69 13.37 8.67 17.33 17.33 34.65 34.65 69.30

100 ml 50 100 50 100 50 100 50 100

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes to Part II - effective 1 August 2009 (continued)

DASATINIB Tab 20 mg......................................Sprycel Tab 50 mg......................................Sprycel Tab 70 mg......................................Sprycel DESFLURANE Liq 240 ml bottle ............................Suprane ENOXAPARIN SODIUM Inj 20 mg .......................................Clexane Inj 40 mg .......................................Clexane Inj 60 mg .......................................Clexane Inj 80 mg .......................................Clexane Inj 100 mg .....................................Clexane Inj 120 mg .....................................Clexane Inj 150 mg .....................................Clexane ENTECAVIR Tab 0.5 mg.....................................Baraclude EPIRUBICIN Inj 2 mg per ml, 5 ml ( price) ........Epirubicin Ebewe Inj 2 mg per ml, 25 ml ( price) ......Epirubicin Ebewe Inj 2 mg per ml, 50 ml ( price) ......Epirubicin Ebewe Inj 2 mg per ml, 100 ml ( price) ....Epirubicin Ebewe FENTANYL CITRATE (amended chemical name) Inj 50 μg per ml, 2 ml .....................Hospira Inj 50 μg per ml, 10 ml ...................Hospira 3,774.06 6,214.20 7,692.58 1,230.00 39.20 52.30 78.85 105.12 135.20 168.00 192.00 400.00 25.00 87.50 155.00 310.00 60 60 60 6 10 10 10 10 10 10 10 30 1 1 1 1 1% 1% 1% 1% Oct-09 Oct-09 Oct-09 Oct-09 Hospira Pharmorubicin Hospira Pharmorubicin Hospira Pharmorubicin Hospira Pharmorubicin 1% 1% 1% 1% 1% 1% 1% 1% Nov-09 Aug-09 Aug-09 Aug-09 Aug-09 Aug-09 Aug-09 Aug-09 (B) (B) (B) (B) (B) (B) (B) (B)

6.10 15.65

5 5

Nupentin 5% Aug-09 Neurontin GABAPENTIN Cap 100 mg ( price) .....................Nupentin 7.16 100 Cap 300 mg ( price) .....................Nupentin 11.50 100 Cap 400 mg ( price) .....................Nupentin 14.75 100 Note – The DV limit of 5% applies to the gabapentin chemical rather than each individual line item. Note – Neurontin cap 100 mg, 300 mg and 400 mg, and tab 600 mg delisted 1 August 2009. ISOFLURANE Liq 250 ml bottle ............................Aerrane 540.00 6 1% Nov-09 Forthane Rhodia

Note – Forthane liq 250 ml bottle to be delisted 1 November 2009

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes to Part II - effective 1 August 2009 (continued)

LEUPRORELIN Inj 3.75 mg prefilled syringe............Lucrin Depot PDS Inj 11.25 mg prefilled syringe ..........Lucrin Depot PDS Inj 30 mg prefilled syringe...............Lucrin Depot PDS NEVIRAPINE Oral suspension 10 mg per ml ........Viramune Suspension Tab 200 mg....................................Viramune OIL IN WATER EMULSION Crm................................................healthE Fatty Cream PARAFFIN Yellow soft .....................................API SAQUINAVIR Tab 500 mg....................................Invirase Note – Invirase to be delisted 1 February 2010 221.60 591.68 1,109.40 1 1 1

134.55 319.80 2.80

240 ml 60 500 g

1% 1%

Oct-09 Oct-09

(B) (B)

1.04

10 g

Oct-09

Dal Orion

556.59

120

SEVOFLURANE Liq 250 ml bottle ............................Baxter 1,230.00 Note – Abbott Sevorane to be delisted 1 November 2009. SODIUM HYALURONATE Opthalmic inj 4 mg per ml ...............Healon GV Opthalmic soln 10 mg per ml ..........Healon Clear 50.00 35.00

Nov-09

Sevorane

1 0.85 ml 60

1% 1%

Oct-09 Oct-09

(B) Provisc

TAMOXIFEN CITRATE Tab 20 mg......................................Tamoxifen Sandoz 6.66

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Chemical and presentation

Brand

Section H changes to Part IV

Effective 1 October 2009

L-ORNITHINE L-ASPARTATE (LOLA) S29 Sach 5 g mg For patients with chronic hepatic encephalopathy who have not responded to treatment with lactulose Note – correction of pack size only. Pamisol Aredia Inj 6 mg per ml, 10 ml Pamisol Inj 9 mg per ml, 10 ml Pamisol For malignant hypercalcaemia, metastatic breast cancer – predominant lytic bone metastases, myeloma with lytic bone metastases, control of pain due to lytic bone metastases in addition to standard care (analgesics + radiotherapy), Gaucher disease with established bone disease. PAMIDRONATE DISODIUM Inj 3 mg per ml, 10 ml

Effective 1 August 2009

PEGFILGRASTIM Inj 6 mg per 0.6 ml prefilled syringe Indefinite supply for any appropriate indication for the management of patients with cancer.

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Index

Pharmaceuticals and brands A Accu-Chek Performa .................................... 26, 35 Aciclovir ............................................................ 39 Actos ................................................................. 26 Aerrane .............................................................. 42 Alendronate for osteoporosis .............................. 19 Alendronate sodium ........................................... 35 Alendronate sodium with cholecalciferol ....... 17, 35 Alpha-Bromocriptine .......................................... 34 Alpha-Keri Lotion ............................................... 27 Aminoacid formula without phenylalanine ........... 18 Amsacrine ......................................................... 30 Amsidine ........................................................... 30 Amsidyl ............................................................. 30 Anastrozole-DP .................................................. 24 Andriol Testocaps .............................................. 18 Apo-Bromocriptine ............................................. 18 Apo-Clopidogrel ........................................... 29, 39 APO-go .............................................................. 31 Apo-Moclobemide........................................ 28, 37 Apomorphine hydrochloride ............................... 31 Aprepitant .................................................... 17, 35 Aredia ................................................................ 44 Arrow-Azithromycin ........................................... 23 Arrow-Clopidogrel ........................................ 18, 39 Atenolol ............................................................. 41 Atropine sulphate ......................................... 26, 35 Azathioprine ....................................................... 31 Azithromycin ...................................................... 23 Azol ............................................................. 29, 39 B Baraclude .................................................... 23, 42 B-D Micro-Fine................................................... 29 Baclofen ................................................ 27, 35, 39 Betadine............................................................. 41 Betadine Skin Prep ....................................... 29, 41 Betahistine dihydrochloride........................... 29, 39 Betaloc CR ............................................. 22, 29, 40 Betamethasone valerate ............................... 27, 35 Beta Scalp ................................................... 27, 35 Blood glucose diagnostic test meter ....... 17, 35, 39 Blood glucose diagnostic test strip ... 17, 26, 31, 35 Bromocriptine mesylate................................ 18, 34 Budesonide .................................................. 29, 39 Butacort Aqueous ........................................ 29, 39 C Calamine...................................................... 26, 33 Cancidas............................................................ 39 Carbohydrate supplement................................... 31 Carboplatin .................................................. 28, 35 Carboplatin Ebewe ....................................... 28, 35 CareSens ..................................................... 17, 35 CareSens II .................................................. 17, 35 CareSens POP ............................................. 17, 35 Caspofungin....................................................... 39 Catapres ...................................................... 26, 36 Catapres-TTS-1 ........................................... 26, 36 Catapres-TTS-2 ........................................... 26, 36 Catapres-TTS-3 ........................................... 26, 36 Chlorhexidine ..................................................... 39 Cilazapril ............................................................ 31 Clarithromycin.............................................. 17, 19 Clexane .............................................................. 42 Clobetasol propionate................................... 27, 35 Clonazepam ....................................................... 39 Clonidine...................................................... 26, 36 Clonidine hydrochloride .......................... 26, 28, 36 Clopidogrel ............................................ 18, 29, 39 Clopine .............................................................. 41 Clopixol........................................................ 18, 41 Clozapine ........................................................... 41 Colifoam ...................................................... 26, 37 Cosopt ......................................................... 28, 36 Cyclosporin A .................................................... 24 D Dasatinib............................................................ 42 Desflurane ......................................................... 42 DM Ject ....................................................... 18, 40 DP-Anastrozole .................................................. 24 D-Zol ........................................................... 29, 39 Danazol........................................................ 29, 39 Dermol......................................................... 27, 35 Diabetic enteral feed 1kcal/ml ............................. 32 Diazepam............................................... 34, 36, 39 Diclocil .............................................................. 32 Dicloxacillin........................................................ 32 Dixarit .......................................................... 28, 36 Dorzolamide hydrochloride with timolol maleate.......................................... 28, 36 E Elemental formula .............................................. 18 Emend Tri-Pack ........................................... 17, 35 Eligard ......................................................... 27, 37 Enoxaparin sodium............................................. 42 Entecavir ...................................................... 23, 42 Epirubicin........................................................... 42 Epirubicin Ebewe................................................ 42 Ethinyloestradiol with gestodene ......................... 32 Ethinyloestradiol with levonorgestrel ................... 32 F Fentanyl citrate................................................... 42 Fleet Glycerin Suppositories ............................... 31 Flixotide ............................................................. 36 Flixotide Accuhaler ............................................. 36

Index

Pharmaceuticals and brands Flucloxacillin sodium .................................... 27, 36 Flucon.......................................................... 29, 33 Fluorometholone .......................................... 29, 33 Flutamide ..................................................... 29, 40 Flutamin ....................................................... 29, 40 Fluticasone ........................................................ 36 Foremount Child’s Silicone Mask ........................ 21 Fortimel ............................................................. 29 Fosamax ............................................................ 35 Fosamax Plus .............................................. 17, 35 G Gabapentin ........................................................ 42 Gentamicin sulphate ..................................... 27, 36 Gluten free pasta ................................................ 34 Glycerol ............................................................. 31 Glyceryl trinitrate ................................................ 36 Goserelin acetate ............................................... 22 H Habitrol .............................................................. 22 Healon Clear ...................................................... 43 Healon GV.......................................................... 43 healthE............................................................... 39 healthE Fatty Cream ........................................... 43 Heparinised saline .................................. 17, 34, 37 Heparin sodium...................................... 17, 26, 37 Hydrocortisone ............................................ 27, 37 Hydrocortisone acetate ................................ 26, 37 Hydroxyethyl starch 130/0.4 .............................. 40 Hydroxyethyl starch 200/0.5 .............................. 37 Hysite ................................................................ 18 Hytrin................................................................. 31 I Indomethacin ..................................................... 31 Insulin pen needles................................. 18, 29, 40 Insulin syringes, disposable with attached needle ......................................... 18, 40 Inhibace ............................................................. 31 Invirase .............................................................. 43 Isentress ...................................................... 17, 38 Isoflurane ........................................................... 42 Isotretinoin ................................................... 18, 40 K Kenacomb ......................................................... 32 Kenacort-A......................................................... 32 Ketone blood beta-ketone electrodes .................. 21 Klacid ................................................................ 19 Klamycin...................................................... 17, 19 Konakion ..................................................... 34, 38 Konakion MM..................................................... 19 L Labetalol ............................................................ 31 Lamotrigine.................................................. 34, 40 Latanoprost........................................................ 18 Leuprorelin............................................. 27, 37, 43 Levodopa with carbidopa ....................... 20, 28, 37 Lignocaine ......................................................... 40 Lioresal Intrathecal ............................................. 39 L-ornithine l-aspartate (lola) ............................... 44 Lucrin Depot PDS............................................... 43 M Mask for spacer device ...................................... 21 Methylprednisolone sodium succinate .......... 27, 37 Metoprolol succinate .............................. 21, 29, 40 Minulet 28.......................................................... 32 Moclobemide ............................................... 28, 37 Mogine ........................................................ 34, 40 Morphine hydrochloride................................ 28, 38 Morphine sulphate........................................ 28, 38 N Naproxen ..................................................... 27, 38 Neoral ................................................................ 24 Nevirapine .......................................................... 43 Nicotine ............................................................. 22 Nicotinell ............................................................ 22 Nitronal .............................................................. 36 Noflam 250 .................................................. 27, 38 Noflam 500 .................................................. 27, 38 Nupentin ............................................................ 42 O Oil in water emulsion .......................................... 43 Ondansetron hydrochloride................................. 41 Optium 10 second test ....................................... 31 Optium Blood Ketone Test Strips ........................ 21 Optium Xceed .................................................... 39 Oral feed 1kcal/ml .............................................. 29 Oratane ........................................................ 18, 40 Orgran ............................................................... 34 Oxytocin ...................................................... 27, 38 Oxytocin with ergometrine maleate ..................... 38 P Pacifen ........................................................ 27, 35 Pacific Atenolol .................................................. 41 Paclitaxel ..................................................... 34, 41 Paclitaxel Ebewe .......................................... 34, 41 Paediatric oral feed 1kcal/ml............................... 31 Pamidronate disodium ....................................... 44 Pamisol ............................................................. 44 Pancuronium bromide ........................................ 38 Paraffin .............................................................. 43 Parnate S29 ....................................................... 24 Pediasure........................................................... 31 Pegfilgrastim ...................................................... 44 Pegatron Combination Therapy ..................... 33, 34 Pegylated interferon alpha-2b with ribavirin ......... 33

Index

Pharmaceuticals and brands Pentastarch........................................................ 37 Pepti Junior Gold................................................ 18 Peptisorb ........................................................... 34 Phytomenadione .................................... 19, 34, 38 Pilocarpine ......................................................... 34 Pilocarpine oral liquid ......................................... 25 Pilopt ................................................................. 34 Pioglitazone ....................................................... 26 PKU Anamix Infant ............................................. 18 PKU Lophlex LQ ................................................. 18 Plavix ................................................................. 29 Polycose............................................................ 31 Potassium chloride ...................................... 26, 38 Povidone iodine ........................................... 29, 41 Pro-Pam ................................................ 34, 36, 39 Q Q 300 .......................................................... 28, 38 Quinine sulphate .......................................... 28, 38 R Raltegravir potassium................................... 17, 38 RA-Morph .................................................... 28, 38 Requip ............................................................... 32 Requip Follow-on Pack....................................... 32 Requip Starter Pack............................................ 32 Resource Diabetic TF RTH.................................. 32 Rheumacin ........................................................ 31 Risperidone.................................................. 17, 38 Risperon ...................................................... 17, 38 Rivotril ............................................................... 39 Ropinirole hydrochloride..................................... 32 S Saquinavir .......................................................... 43 SC Profi-Fine................................................ 18, 40 Semi-elemental enteral feed 1kcal/ml.................. 34 Sevoflurane ........................................................ 43 Sevredol ...................................................... 28, 38 Sinemet ....................................................... 28, 37 Sinemet CR............................................ 20, 28, 37 Sodium cromoglycate ........................................ 28 Sodium hyaluronate ........................................... 43 Solu-Medrol ................................................. 27, 37 Space Chamber ................................................. 21 Spacer device .................................................... 21 Span-K ........................................................ 26, 38 Sprycel .............................................................. 42 StarQuin 200 6% ................................................ 37 Suprane ............................................................. 42 Syntocinon................................................... 27, 38 Syntometrine................................................ 27, 38 T Tamoxifen citrate................................................ 43 Tamoxifen Sandoz.............................................. 43 Terazosin hydrochloride ..................................... 31 Testosterone undecanoate.................................. 18 Thioprine ........................................................... 31 Timolol maleate.................................................. 38 Timoptol XE ....................................................... 38 Trandate ............................................................ 31 Tranylcypromine sulphate .................................. 24 Triamcinolone acetonide .................................... 32 Triamcinolone acetonide with gramicidin, neomycin and nystatin .................................... 32 Trimipramine maleate ......................................... 34 Triphasil 28 ........................................................ 32 Tripress ............................................................. 34 V Vergo 16 ...................................................... 29, 39 Vinorelbine ......................................................... 29 Viramune ........................................................... 43 Viramune Suspension ........................................ 43 Vitadol C ............................................................ 26 Vitamin a with vitamins d and c .......................... 26 Volumatic .......................................................... 21 Voluven.............................................................. 40 W Wool fat with mineral oil ..................................... 27 X Xylocaine Jelly ................................................... 40 Z Zofran ................................................................ 41 Zoladex .............................................................. 22 Zuclopenthixol hydrochloride ........................ 18, 41

Pharmaceutical Management Agency Level 9, 40 Mercer Street, PO Box 10-254, Wellington 6143, New Zealand Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz Freephone Information line (9am-5pm weekdays) 0800 66 00 50 ISSN 1179-3724

PHARMAC is the Government agency responsible for deciding which medicines are subsidised for New Zealanders. It manages spending on pharmaceuticals for the District Health Boards, and ensures that a comprehensive list of medicines (the Pharmaceutical Schedule) is subsidised for New Zealanders, and that the list of medicines continues to grow to meet the needs of patients.

Metadata

Title

Section H - effective 1 October 2009

Abstract

Pharmaceutical Management Agency Update New Zealand Pharmaceutical Schedule Effective 1 October 2009 Section H cumulative for August, September and October 2009 Contents Summary of PHARMAC decision effective 1 October 2009 …. 3 Clarithromycin for helcobacter pylori eradication… 6 Diabetes Management…

Page 1

Note

This text has been extracted from the source PDF document.

Also available as plain text.

Please contact webmaster to discuss alternative format options.